Antibodies that recognize RSV pre-F protein and uses thereof

Monoclonal antibodies targeting new epitopes on the RSV pre-F protein provide effective and affordable protection against RSV, addressing the limitations of current treatments and vaccines by enhancing neutralization capacity and reducing infection rates.

JP2024544687APending Publication Date: 2024-12-03XIAMEN UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024533280
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-06
Filing Date
2022-08-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current RSV vaccines and treatments, such as Synagis and Nirsevimab, are limited by insufficient neutralization capacity, high production costs, and high prices, and there is a lack of commercially available drugs for RSV prevention and treatment in China, posing a significant health burden, especially in children and older adults.

Method used

Development of monoclonal antibodies that specifically bind to new epitopes between antigenic sites φ and V or between sites II and V of the RSV pre-F protein, offering high neutralizing activity and broad-spectrum protection against RSV strains.

Benefits of technology

The monoclonal antibodies demonstrate strong neutralizing activity against RSV, preventing infection and reducing hospitalizations, with potential for broad-spectrum application across multiple strains and improved safety and affordability compared to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544687000001_ABST
    Figure 2024544687000001_ABST
Patent Text Reader

Abstract

summary The present invention relates to the field of immunology and molecular virology, in particular to the field of prevention and treatment of RSV, specifically to a monoclonal antibody capable of specifically binding to a new epitope between the Φ epitope and the V epitope on the pre-F protein, or between the II epitope and the V epitope, and its use in the detection, prevention and / or treatment of RSV infection and / or diseases caused by said infection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present application relates to the fields of immunology and molecular virology, in particular the prevention and treatment of RSV. In particular, the present application provides monoclonal antibodies capable of specifically binding to a novel epitope located between antigenic sites φ and V of the pre-F protein, or a novel epitope located between antigenic sites II and V, and their use for the detection, prevention and / or treatment of RSV infection and / or diseases caused by said infection. [Background technology]

[0002] Human respiratory syncytial virus (RSV) is the most common pathogen causing acute lower respiratory tract infections in children under 5 years of age and is also the leading cause of hospitalization for lower respiratory tract infections in infants and young children. Almost all infants and children under 2 years of age are infected with RSV, and infants and children under 6 months of age are the main group of people hospitalized for RSV infection, accounting for approximately 50% of all hospitalizations. Globally, there are more than 30 million cases of lower respiratory tract infection caused by RSV infection each year, resulting in 66,000 to 239,000 deaths, including more than 3 million hospitalizations (Ting Shi, David A McAllister, et al., Lancet, 390 (2017) 946-958; Geoghegan S, Erviti A, et al., Am J Respir Crit Care Med 195 (2017) 96-103). Compared with other respiratory viral infections, children infected with RSV have a higher disease burden; in particular, infants and children under 6 months of age have a higher disease burden than children aged 6 to 24 months, including higher ICU admission rates, hospitalization costs, and longer hospital stays. RSV infection increases the risk of severe pediatric pneumonia by 14-fold (The Pneumonia Etiology Research for Child Health (PERCH) Study Group, Lancet, 394 (2019) 757-779). The prevalence of RSV infection in premature infants with bronchial and pulmonary underdevelopment, congenital heart disease, and immunodeficiency reaches 50% to 70% (AC Cooper, NC Banasiak, et al., Pediatr Nurs, 29 (2003) 452 -456). In addition, the elderly are also susceptible to RSV, with over 12,000 deaths caused by RSV infection each year. RSV is also the leading causative agent of lower respiratory tract infections in Chinese children. Approximately 215,000–500,000 infants and children are hospitalized with RSV infections each year in China (Li Y, Johnson EK, et al., Lancet Respir Med, 2021, 9 (2): 175-185).

[0003] Currently, there is no commercially available safe and effective RSV vaccine. The only neutralizing antibody that recognizes the RSV fusion glycoprotein (palivizumab, trade name: Synagis) has been approved by the US FDA for the prevention of severe lower respiratory tract infections caused by RSV in patients such as premature infants and high-risk infants and young children with chronic lung disease, bronchial and pulmonary malformations, and congenital heart disease. However, Synagis is not widely used, being used only for "infants and young children at high risk of infection" due to its insufficient neutralizing ability, high production cost, and high price. In addition, Sanofi Pasteur and AstraZeneca have jointly developed a new generation RSV prophylactic drug, "Nirsevimab," based on the human antibody D25. Nirsevimab is a prophylactic monoclonal antibody with an extended half-life, and one single dose of intramuscular injection of nirsevimab provides sustained protection for up to 5 months in infants and young children, allowing infants and young children to safely survive the entire RSV season. Phase IIb results of clinical trials showed that nirsevimab reduced the rates of medical consultations and hospitalizations by 70.1% and 78.4%, respectively, compared with the control group (M Pamela Griffin, Yuan Yuan, et al., N Engl J Med, 383(2020) 415-425). Currently, nirsevimab has been designated a "breakthrough treatment" by the US FDA. In January 2021, the monoclonal antibody nirsevimab was listed as a "breakthrough therapy" in China. Currently, there are no RSV-specific prophylactic or treatment drugs commercially available in China.

[0004] RSV is a single-stranded, negative-stranded, non-segmented RNA virus that belongs to the pneumovirus family of the Adhesionviridae family. It has 15,222 nucleotides, contains 10 genes, and encodes 11 proteins. Among them, the fusion (F) protein, a type I transmembrane protein, has a full length of 574 amino acids and is currently the main target protein for RSV vaccine and antibody development. The F protein of RSV exists in two conformations: pre-fusion (pre-F) and post-fusion (post-F). Pre-F is a high-energy, metastable pre-fusion conformation that mediates fusion of the viral envelope with the cell membrane; after fusion, pre-F allosterically transforms into post-F, a highly stable post-fusion conformation. Compared with the post-F protein, the pre-F protein has more neutralizing epitopes with higher activity, which can induce the production of antibodies with high neutralizing activity.

[0005] In summary, RSV causes serious harm to children and significant health and medical burdens worldwide. There is an urgent need in China to develop independent proprietary antibodies with broad spectrum and high neutralizing activity for the prevention and / or treatment of RSV, and the developed antibodies can be used to prevent and / or treat RSV infection in children. Summary of the Invention

[0006] Contents of the Application Currently, six neutralizing epitopes (sites φ, I, II, III, IV, and V) have been found in pre-F and post-F. Among them, sites φ and V are epitopes that are specifically present in pre-F with high activity, and sites I, II, III, and IV are present in both pre-F and post-F. Site φ is specifically located at the membrane-distal end of the pre-F trimer. This epitope includes the α4 helix (residues 196-209) of the F1 subunit and a partial region of F2 (residues 62-69); and both regions undergo dramatic changes during the allosteric process from pre-fusion to post-fusion. Antibodies that recognize this epitope include D25, 5C4, and AM22. All three antibodies are pre-F specific antibodies with strong neutralizing activity, and their neutralizing ability is nearly 100-fold higher than that of palivizumab. Site I is a linear epitope present in both pre-F and post-F, consisting of residues 387-392 located between the α8 helix and β14; and an antibody that recognizes this epitope is 131-2, but this antibody has only a weak neutralizing ability. Site II is present in both pre-F and post-F, and consists of the α6 helix, the α7 helix, and the loop between them (residues 255-276). Representative antibodies that recognize this epitope include mouse antibody 1129, humanized palivizumab, and the second-generation antibody motavizumab derived from palivizumab; and these antibodies show intermediate neutralizing ability. Site III is present in both pre-F and post-F. A representative antibody that recognizes this epitope is MPE8, which prefers to bind to proteins in the pre-F conformation. MPE8 has a broad spectrum of neutralizing activity and can neutralize four types of viruses, hRSV, BRSV, hMPV, and PVM. Site IV also exists in both pre-F and post-F and has a linear structure composed of residues 422-438; and the representative antibody that recognizes this epitope is 101F, which shows moderate neutralizing ability.Site V is specifically present in the pre-F three-dimensional protein structure and is an epitope composed of residues 146-194 and 287-300 of the protein trimer; the antibody AM14, which recognizes this epitope, can only bind to the two monomer binding regions of pre-F and has high neutralizing ability.

[0007] After extensive research, the inventors of the present application unexpectedly developed a monoclonal antibody that specifically binds to a new epitope located between antigenic site φ and site V of the pre-F protein, or a new epitope located between antigenic site II and site V. The antibody of the present application can specifically recognize the pre-F conformation, effectively neutralize RSV, and prevent or inhibit RSV from fusing with cells. Thus, the present application provides the following aspects:

[0008] Antibody or antigen-binding fragment thereof 5B11 In a first aspect, the present application provides an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a respiratory syncytial virus (RSV) pre-F protein, wherein the epitope includes at least six amino acid residues (e.g., non-contiguous amino acid residues) within amino acid residues 160-182 of the pre-F protein and includes amino acid residues 294-295 of the pre-F protein.

[0009] In certain embodiments, the epitope comprises at least amino acid residues at positions 161, 165, 166, 169, 180, 182, 294, and 295. In a specific embodiment, the epitope further comprises the amino acid residue at position 196. In a specific embodiment, the epitope further comprises amino acid residues 162 and 184. In certain embodiments, the epitope comprises amino acid residues 161-182 (eg, amino acid residues 161-184) and amino acid residues 294-295.

[0010] In certain embodiments, the epitope is a conformational epitope. In certain embodiments, the amino acid residue positions are determined according to SEQ ID NO:1. In certain embodiments, the epitope includes at least E161, N165, K166, S169, S180, S182, E294, and E295; in certain embodiments, the epitope further includes K196; in certain embodiments, the epitope also includes G162 and G184.

[0011] In a second aspect, the present application provides a method for producing a method for treating a pulmonary circulation comprising the steps of: (a) a heavy chain variable region (VH) comprising the following three CDRs: a VH CDR1 comprising the sequence set forth in SEQ ID NO:5 or a variant thereof, a VH CDR2 comprising the sequence set forth in SEQ ID NO:6 or a variant thereof, and a VH CDR3 comprising the sequence set forth in SEQ ID NO:7 or a variant thereof; and / or (b) a light chain variable region (VL) comprising the following three CDRs: a VL CDR1 comprising the sequence set forth in SEQ ID NO: 8 or a variant thereof, a VL CDR2 comprising the sequence set forth in SEQ ID NO: 9 or a variant thereof, and a VL CDR3 comprising the sequence set forth in SEQ ID NO: 10 or a variant thereof; Including, Provided herein are antibodies or antigen-binding fragments thereof, wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or wherein the variant has one or more amino acid substitutions, deletions, or additions (e.g., one, two, or three amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived. In certain embodiments, the substitutions are conservative substitutions.

[0012] In certain embodiments, the antibody or antigen-binding fragment thereof is capable of specifically binding a RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof competes with the antibody or antigen-binding fragment thereof of the first aspect for binding to the RSV pre-F protein. In certain embodiments, competitive binding refers to being able to interfere with at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, or preferably at least 99% of the binding of the antibody or antigen-binding fragment thereof of the first aspect to the RSV pre-F protein. Competitive binding can be measured by competitive binding assays.

[0013] Competitive binding assays are well known to those skilled in the art. Competitive binding assays are immunoassays in which unknown substances are detected and quantified by the ability of the unknown substance to inhibit the binding of a labeled known antigen to the antibody to which it specifically binds, and are also called competitive inhibition assays. An exemplary method includes: precoating an antigen onto a microwell plate, then adding serially diluted unlabeled antibodies to be tested and a labeled known monoclonal antibody (i.e., the antibody or antigen-binding fragment thereof described in the first embodiment) having a specific concentration to said precoated microwell plate for incubation, and then, after washing, measuring the amount of the known antibody bound to the plate in the presence of the antibody to be tested at different dilutions. The higher the ability of the antibody to be tested to compete with the known antibody for binding to the antigen, the lower the ability of the known antibody to bind to the antigen, the less the known antibody will bind to the plate. Typically, the antigen is precoated onto a 96-well microplate and the ability of the monoclonal antibody being tested to interfere with a labeled known monoclonal antibody is measured by radioimmunoassay, enzyme immunoassay such as ELISA, or fluorescent immunoassay.

[0014] In certain embodiments, the epitope recognized by the antibody or antigen-binding fragment thereof is identical to or overlaps in space with the epitope recognized by the antibody or antigen-binding fragment thereof of the first aspect, such that the antibody or antigen-binding fragment thereof interferes with binding of the antibody or antigen-binding fragment thereof of the first aspect to the RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of the first aspect.

[0015] In certain embodiments: (i) the antibody or antigen-binding fragment thereof comprises: three heavy chain CDRs: a VH CDR1 having the sequence set forth in SEQ ID NO:5, a VH CDR2 having the sequence set forth in SEQ ID NO:6, and a VH CDR3 having the sequence set forth in SEQ ID NO:7; and / or three light chain CDRs: a VL CDR1 having the sequence set forth in SEQ ID NO:8, a VL CDR2 having the sequence set forth in SEQ ID NO:9, and a VL CDR3 having the sequence set forth in SEQ ID NO:10; and / or (ii) The antibody or antigen-binding fragment thereof comprises: the three CDRs contained in the heavy chain variable region (VH) set forth in SEQ ID NO: 3 or 60; and / or the three CDRs contained in the light chain variable region (VL) set forth in SEQ ID NO: 4 or 61. In certain embodiments, the three CDRs contained in the VH and / or the three CDRs contained in the VL are defined according to the Kabat, IMGT or Chothia numbering systems.

[0016] In certain embodiments, the antibody or antigen-binding fragment thereof comprises one of the following: a VH comprising a sequence as set forth in SEQ ID NO: 3 or a variant thereof, and / or a VL comprising a sequence as set forth in SEQ ID NO: 4 or a variant thereof; wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with respect to the sequence from which it is derived, or the variant has one or more amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions) with respect to the sequence from which it is derived. In certain embodiments, the substitutions are conservative substitutions.

[0017] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a VH set forth in SEQ ID NO:3, and / or a VL set forth in SEQ ID NO:4. In certain embodiments, the antibody or antigen-binding fragment thereof is humanized and comprises framework sequences derived from a human immunoglobulin. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain framework sequence derived from a human heavy chain germline sequence, and a light chain framework sequence derived from a human light chain germline sequence, and the heavy chain framework sequence and / or the light chain framework sequence optionally comprise backmutations of human residues to murine residues. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a VH set forth in SEQ ID NO:60, and / or a VL set forth in SEQ ID NO:61.

[0018] In a third aspect, the present application also provides an antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 5B11 or an antigen-binding fragment thereof) described in the second aspect for binding to the RSV pre-F protein. In certain embodiments, competitive binding refers to being able to interfere with at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, or preferably at least 99% of the binding of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 5B11 or an antigen-binding fragment thereof) described in the second aspect to the RSV pre-F protein. Competitive binding can be measured by competitive binding assays as described above.

[0019] In certain embodiments, the epitope recognized by the antibody or antigen-binding fragment thereof is identical to or overlaps in space with the epitope recognized by the antibody or antigen-binding fragment thereof of the second aspect (e.g., monoclonal antibody 5B11 or an antigen-binding fragment thereof) such that the antibody or antigen-binding fragment thereof interferes with binding of the antibody or antigen-binding fragment thereof of the second aspect (e.g., monoclonal antibody 5B11 or an antigen-binding fragment thereof) to the RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of the second aspect (e.g., monoclonal antibody 5B11 or an antigen-binding fragment thereof).

[0020] 6B2 In a fourth aspect, the present application provides an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a respiratory syncytial virus (RSV) pre-F protein, wherein the epitope includes at least five amino acid residues (e.g., non-contiguous amino acid residues) within amino acid residues 160-185 and 290-295 of the pre-F protein.

[0021] In a specific embodiment, the epitope comprises at least amino acid residues at positions 161, 162, 184, 293 and 294. In a specific embodiment, the epitope comprises amino acid residues 161-182 and 293-294.

[0022] In certain embodiments, the epitope is a conformational epitope. In certain embodiments, the amino acid residue positions are determined according to SEQ ID NO:1. In certain embodiments, the epitope includes at least E161, G162, G184, K293, and E294.

[0023] In a fifth aspect, the present application provides a method for producing a method for treating a pulmonary circulation comprising the steps of: (a) a heavy chain variable region (VH) comprising the following three CDRs: a VH CDR1 comprising the sequence set forth in SEQ ID NO: 13 or a variant thereof, a VH CDR2 comprising the sequence set forth in SEQ ID NO: 14 or a variant thereof, and a VH CDR3 comprising the sequence set forth in SEQ ID NO: 15 or a variant thereof; and / or (b) a light chain variable region (VL) comprising the following three CDRs: a VL CDR1 comprising the sequence set forth in SEQ ID NO: 16 or a variant thereof, a VL CDR2 comprising the sequence set forth in SEQ ID NO: 17 or a variant thereof, and a VL CDR3 comprising the sequence set forth in SEQ ID NO: 18 or a variant thereof; Including, Provided herein are antibodies or antigen-binding fragments thereof, wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or wherein the variant has one or more amino acid substitutions, deletions, or additions (e.g., one, two, or three amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived. In certain embodiments, the substitutions are conservative substitutions.

[0024] In certain embodiments, the antibody or antigen-binding fragment thereof is capable of specifically binding to a RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof competes with an antibody or antigen-binding fragment thereof of the fourth aspect for binding to the RSV pre-F protein. In certain embodiments, competitive binding refers to being able to interfere with at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, or preferably at least 99% of the binding of the antibody or antigen-binding fragment thereof according to the fourth aspect to the RSV pre-F protein. Competitive binding can be measured by competitive binding assays.

[0025] In certain embodiments, the epitope recognized by the antibody or antigen-binding fragment thereof is identical to or overlaps in space with the epitope recognized by the antibody or antigen-binding fragment thereof of the fourth aspect, such that the antibody or antigen-binding fragment thereof interferes with binding of the antibody or antigen-binding fragment thereof of the fourth aspect to the RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of the fourth aspect.

[0026] In certain embodiments: (i) the antibody or antigen-binding fragment thereof comprises: three heavy chain CDRs: a VH CDR1 having the sequence set forth in SEQ ID NO: 13, a VH CDR2 having the sequence set forth in SEQ ID NO: 14, and a VH CDR3 having the sequence set forth in SEQ ID NO: 15; and / or three light chain CDRs: a VL CDR1 having the sequence set forth in SEQ ID NO: 16, a VL CDR2 having the sequence set forth in SEQ ID NO: 17, and a VL CDR3 having the sequence set forth in SEQ ID NO: 18; and / or (ii) The antibody or antigen-binding fragment thereof comprises: the three CDRs contained in the heavy chain variable region (VH) set forth in SEQ ID NO: 11; and / or the three CDRs contained in the light chain variable region (VL) set forth in SEQ ID NO: 12. In certain embodiments, the three CDRs contained in the VH and / or the three CDRs contained in the VL are defined according to the Kabat, IMGT or Chothia numbering systems.

[0027] In certain embodiments, the antibody or antigen-binding fragment thereof comprises one of the following: a VH comprising a sequence as set forth in SEQ ID NO: 11 or a variant thereof, and / or a VL comprising a sequence as set forth in SEQ ID NO: 12 or a variant thereof; wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with respect to the sequence from which it is derived, or the variant has one or more amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions) with respect to the sequence from which it is derived. In certain embodiments, the substitutions are conservative substitutions. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a VH set forth in SEQ ID NO:11, and / or a VL set forth in SEQ ID NO:12.

[0028] In a sixth aspect, the present application also provides an antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 6B2 or an antigen-binding fragment thereof) described in the fifth aspect for binding to the RSV pre-F protein. In certain embodiments, competitive binding refers to being able to interfere with at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, or preferably at least 99% of the binding of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 6B2 or an antigen-binding fragment thereof) described in the fifth aspect to the RSV pre-F protein. Competitive binding can be measured by competitive binding assays as described above.

[0029] In certain embodiments, the epitope recognized by the antibody or antigen-binding fragment thereof is identical to or overlaps in space with the epitope recognized by the antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 6B2 or an antigen-binding fragment thereof) described in the fifth aspect, such that the antibody or antigen-binding fragment thereof interferes with binding of the antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 6B2 or an antigen-binding fragment thereof) described in the fifth aspect to the RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 6B2 or an antigen-binding fragment thereof) described in the fifth aspect.

[0030] 7G5 In a seventh aspect, the present application provides an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a respiratory syncytial virus (RSV) pre-F protein, wherein the epitope includes at least three amino acid residues (e.g., non-contiguous amino acid residues) within amino acid residues 160 to 185 of the pre-F protein.

[0031] In a specific embodiment, the epitope comprises at least amino acid residues 161, 162, and 184. In a specific embodiment, the epitope comprises amino acid residues 161-182.

[0032] In certain embodiments, the epitope is a conformational epitope. In certain embodiments, the amino acid residue positions are determined according to SEQ ID NO:1. In a particular embodiment, the epitope includes at least E161, G162, and G184.

[0033] In an eighth aspect, the present application provides a method for producing a composition comprising the steps of: (a) a heavy chain variable region (VH) comprising the following three CDRs: a VH CDR1 comprising the sequence set forth in SEQ ID NO: 21 or a variant thereof, a VH CDR2 comprising the sequence set forth in SEQ ID NO: 22 or a variant thereof, and a VH CDR3 comprising the sequence set forth in SEQ ID NO: 23 or a variant thereof; and / or (b) a light chain variable region (VL) comprising the following three CDRs: a VL CDR1 comprising the sequence set forth in SEQ ID NO: 24 or a variant thereof, a VL CDR2 comprising the sequence set forth in SEQ ID NO: 25 or a variant thereof, and a VL CDR3 comprising the sequence set forth in SEQ ID NO: 26 or a variant thereof; Including, Provided herein are antibodies or antigen-binding fragments thereof, wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or wherein the variant has one or more amino acid substitutions, deletions, or additions (e.g., one, two, or three amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived. In certain embodiments, the substitutions are conservative substitutions.

[0034] In certain embodiments, the antibody or antigen-binding fragment thereof is capable of specifically binding to a RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof competes with an antibody or antigen-binding fragment thereof of the seventh aspect for binding to the RSV pre-F protein. In certain embodiments, competitive binding refers to being able to interfere with at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, or preferably at least 99% of the binding of the antibody or antigen-binding fragment thereof according to the seventh aspect to the RSV pre-F protein. Competitive binding can be measured by competitive binding assays.

[0035] In certain embodiments, the epitope recognized by the antibody or antigen-binding fragment thereof is identical to or overlaps in space with the epitope recognized by the antibody or antigen-binding fragment thereof according to the seventh aspect, such that the antibody or antigen-binding fragment thereof interferes with binding of the antibody or antigen-binding fragment thereof of the seventh aspect to the RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of the seventh aspect.

[0036] In certain embodiments: (i) the antibody or antigen-binding fragment thereof comprises: three heavy chain CDRs: a VH CDR1 having the sequence set forth in SEQ ID NO: 21, a VH CDR2 having the sequence set forth in SEQ ID NO: 22, and a VH CDR3 having the sequence set forth in SEQ ID NO: 23; and / or three light chain CDRs: a VL CDR1 having the sequence set forth in SEQ ID NO: 24, a VL CDR2 having the sequence set forth in SEQ ID NO: 25, and a VL CDR3 having the sequence set forth in SEQ ID NO: 26; and / or (ii) The antibody or antigen-binding fragment thereof comprises: the three CDRs contained in the heavy chain variable region (VH) set forth in SEQ ID NO: 19; and / or the three CDRs contained in the light chain variable region (VL) set forth in SEQ ID NO: 20. In certain embodiments, the three CDRs contained in the VH and / or the three CDRs contained in the VL are defined according to the Kabat, IMGT, or Chothia numbering systems.

[0037] In certain embodiments, the antibody or antigen-binding fragment thereof comprises one of the following: a VH comprising a sequence as set forth in SEQ ID NO: 19 or a variant thereof, and / or a VL comprising a sequence as set forth in SEQ ID NO: 20 or a variant thereof; wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with respect to the sequence from which it was derived, or the variant has one or several amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions) with respect to the sequence from which it was derived. In certain embodiments, the substitutions are conservative substitutions. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a VH set forth in SEQ ID NO:19, and / or a VL set forth in SEQ ID NO:20.

[0038] In a ninth aspect, the present application also provides an antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 7G5 or an antigen-binding fragment thereof) described in the eighth aspect for binding to the RSV pre-F protein. In certain embodiments, competitive binding refers to being able to interfere with at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, or preferably at least 99% of the binding of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody 7G5 or an antigen-binding fragment thereof) described in the eighth aspect to the RSV pre-F protein. Competitive binding can be measured by competitive binding assays as described above.

[0039] In certain embodiments, the epitope recognized by the antibody or antigen-binding fragment thereof is identical to or overlaps in space with the epitope recognized by the antibody or antigen-binding fragment thereof of the eighth aspect (e.g., monoclonal antibody 7G5 or an antigen-binding fragment thereof) such that the antibody or antigen-binding fragment thereof interferes with binding of the antibody or antigen-binding fragment thereof of the eighth aspect (e.g., monoclonal antibody 7G5 or an antigen-binding fragment thereof) to the RSV pre-F protein. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of the eighth aspect (e.g., monoclonal antibody 7G5 or an antigen-binding fragment thereof).

[0040] In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof is derived from a mouse. In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof comprises framework region sequences derived from a mouse immunoglobulin.

[0041] In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof is humanized. In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof comprises framework region sequences derived from a human immunoglobulin. In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof comprises: a heavy chain framework region sequence derived from a human heavy chain germline sequence and a light chain framework region sequence derived from a human light chain germline sequence. The heavy chain framework region and / or the light chain framework region optionally comprise backmutations of human residues to murine residues.

[0042] In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof further comprises a constant region derived from a mouse or human immunoglobulin.

[0043] In certain embodiments of any of the above aspects, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region derived from a mouse or human immunoglobulin (e.g., an IgG1, IgG2, IgG3, or IgG4) and the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region derived from a mouse or human immunoglobulin (e.g., an immunoglobulin comprising a λ or κ chain). In a specific embodiment, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region set forth in SEQ ID NO:62, and the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region set forth in SEQ ID NO:63.

[0044] In certain embodiments of any of the above aspects, the antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a (Fab')2, an Fv, a disulfide-linked Fv, an scFv, a diabody, and a single domain antibody (sdAb). In certain embodiments of any of the above aspects, the antibody is a murine antibody, a chimeric antibody, a humanized antibody, a bispecific antibody, or a multispecific antibody.

[0045] In certain embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof has the following characteristics: (a) neutralizing RSV (e.g., RSV type A and / or type B) in vitro or in a subject (e.g., a human); (b) disrupting or inhibiting RSV (e.g., RSV type A and / or type B) from fusion with a cell in vitro or in a subject (e.g., a human); (c) preventing and / or treating RSV (e.g., RSV type A and / or type B) infection or disease associated with RSV (e.g., RSV type A and / or type B) infection (e.g., pneumonia, such as childhood pneumonia); The present invention has one or more of the following:

[0046] In certain embodiments, exemplary strains of RSV type A include the following viral strains as defined in GenBank: KT992094.1, GU591760.1, KJ627328.1, KJ723478.1, KU316139.1, KU316112.1, FJ614813.1, KJ627352.1, KJ627274.1, KU316092.1, and / or HQ317235.1. In certain embodiments, exemplary strains of RSV type B include the following viral strains as defined in GenBank: JN032119.1, KX765905.1, KY249659.1, KJ627302.1, JQ736675.1, KX765900.1, JF714712.1, AF013254.1, AY353550.1, and / or RSV18537 strains. Isolated Nucleic Acid Molecules In a tenth aspect, the present application provides an isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof, its heavy chain variable region, and / or its light chain variable region according to any of the above aspects.

[0047] In certain embodiments, an isolated nucleic acid molecule comprises a first nucleotide sequence encoding a heavy chain or heavy chain variable region of an antibody or antigen-binding fragment thereof of any aspect of the present application, and a second nucleotide sequence encoding a light chain or light chain variable region of an antibody or antigen-binding fragment thereof, wherein the first nucleotide sequence and the second nucleotide sequence are present on the same or different isolated nucleic acid molecules. When the first nucleotide sequence and the second nucleotide sequence are present on different isolated nucleic acid molecules, the isolated nucleic acid molecule described herein comprises a first nucleic acid molecule comprising the first nucleotide sequence and a second nucleic acid molecule comprising the second nucleotide sequence.

[0048] vector In an eleventh aspect, the present application provides a vector comprising the nucleic acid molecule described above. In certain embodiments, the vector is a cloning vector or an expression vector.

[0049] In certain embodiments, a vector comprises a first nucleotide sequence encoding a heavy chain or heavy chain variable region of an antibody or antigen-binding fragment thereof of any aspect of the present application, and a second nucleotide sequence encoding a light chain or light chain variable region of an antibody or antigen-binding fragment thereof, wherein the first nucleotide sequence and the second nucleotide sequence are present on the same or different vectors. When the first nucleotide sequence and the second nucleotide sequence are present on different vectors, the vectors described herein include a first vector comprising the first nucleotide sequence and a second vector comprising the second nucleotide sequence.

[0050] host cell In a twelfth aspect, the present application provides a host cell comprising the nucleic acid molecule or vector described above, including, but not limited to, prokaryotic cells such as bacterial cells (e.g., Escherichia coli cells), and eukaryotic cells such as fungal cells (e.g., yeast cells), insect cells, and animal cells (e.g., mammalian cells such as mouse cells, human cells, etc.).

[0051] Preparation method The antibodies of the present application can be prepared by various methods known in the art, such as genetic engineering and recombinant technology. For example, DNA molecules encoding the heavy and light chains of the antibodies of the present application can be obtained by chemical synthesis or PCR amplification. The resulting DNA molecules are inserted into an expression vector and then transfected into a host cell. The transfected host cell is then cultured under specific conditions and expresses the antibodies of the present application.

[0052] The antibody of the present invention is not limited by its production method, for example, it can be produced by genetic engineering (recombinant technology) or chemical synthesis. The antigen-binding fragment of the present invention can be obtained by hydrolysis of the complete antibody molecule (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992), and Brennan et al., Science 229:81 (1985)). In addition, these antigen-binding fragments can be directly produced by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11: 548-557 (1999); Little et al., Immunol. Today, 21: 364-370 (2000)). For example, Fab' fragments can be obtained directly from host cells; Fab' fragments can be chemically coupled to form F(ab')2 fragments (Carter et al., Bio / Technology, 10: 163-167 (1992)). In addition, Fv, Fab or F(ab')2 fragments can be isolated directly from the culture medium of recombinant host cells. Other techniques for preparing these antigen-binding fragments are well known to those of skill in the art.

[0053] In a thirteenth aspect, the present application provides a method for preparing an antibody or antigen-binding fragment thereof of any aspect of the present application, the method comprising culturing a host cell as described above under conditions that allow expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the culture of the cultured host cells.

[0054] Pharmaceutical Compositions In a fourteenth aspect, the present application provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of any aspect of the present application and a pharma- ceutically acceptable carrier and / or excipient. In certain exemplary embodiments, the pharma- ceutically acceptable carrier and / or excipient comprises a sterile injectable liquid (e.g., an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, the sterile injectable liquid is selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a surfactant-containing solution (e.g., 0.01% polysorbate 20), a pH buffer (e.g., phosphate buffer solution), Ringer's solution, and any combination thereof.

[0055] Use to manufacture medicines In a fifteenth aspect, the present application provides the use of an antibody or antigen-binding fragment thereof of any aspect of the present application in the manufacture of a medicament, wherein the medicament is used to neutralize the pathogenicity of RSV, or to inhibit or prevent fusion of RSV to a cell, or to prevent and / or treat respiratory syncytial virus infection or a disease associated with respiratory syncytial virus infection (e.g., pneumonia, such as childhood pneumonia) in a subject.

[0056] In certain embodiments, the subject is a mammal, such as a human. In certain embodiments, the antibodies or antigen-binding fragments thereof are used alone or in combination with an additional pharma- ceutically active agent.

[0057] Methods for preventing and / or treating diseases In a sixteenth aspect, the present application provides a method for preventing and / or treating respiratory syncytial virus infection or a disease associated with respiratory syncytial virus infection (e.g., pneumonia, such as childhood pneumonia) in a subject (e.g., a human), comprising: administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof of any aspect of the present application, or a pharmaceutical composition of the present application.

[0058] The antibody or antigen-binding fragment thereof of the present invention or the pharmaceutical composition of the present invention may be formulated into any dosage form well known in the medical field, such as tablets, pills, suspensions, emulsions, liquids, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injection solutions, sterile powders for injection and concentrated solutions for injection), inhalants, sprays, etc. The preferred dosage form depends on the intended mode of administration and treatment use. The antibody or antigen-binding fragment thereof or pharmaceutical composition of the present invention should be sterile and stable under the conditions of manufacture and storage. The preferred dosage form is an injection. Such an injection may be a sterile solution for injection. For example, the sterile solution for injection may be prepared by including the required amount of the antibody or antigen-binding fragment thereof of the present invention in a suitable solvent, and optionally including other desired ingredients (including but not limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonicity agents, preservatives, diluents, or any combination thereof) at the same time, followed by filtration sterilization. In addition, the sterile injectable solution may be prepared as a sterile lyophilized powder (e.g., by vacuum drying or lyophilization) for ease of storage and use. Such sterile lyophilized powder may be dispersed in a suitable carrier, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), surfactant-containing solution (e.g., 0.01% polysorbate 20), pH buffer (e.g., phosphate buffer solution), Ringer's solution, and any combination thereof, prior to use.

[0059] The antibody or antigen-binding fragment thereof of the present invention or pharmaceutical composition of the present invention may be administered by any suitable method known in the art, including, but not limited to, oral, buccal, sublingual, ophthalmic, topical, parenteral, rectal, intrathecal, intracisternal, inguinal, intravesical, topical (e.g., powder, ointment or drops) or nasal routes. However, for many therapeutic uses, the preferred route / mode of administration is parenteral (e.g., intravenous or bolus injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Those skilled in the art will appreciate that the route and / or mode of administration will vary depending on the intended purpose. In a specific embodiment, the antibody or antigen-binding fragment thereof or pharmaceutical composition of the present invention is administered by intravenous injection or bolus injection.

[0060] Conjugates In a seventeenth aspect, the present application provides a conjugate comprising the antibody or antigen-binding fragment thereof of any aspect of the present application and a detectable label linked to the antibody or antigen-binding fragment thereof. In certain embodiments, the detectable label is selected from the group consisting of an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g., an acridinium ester, luminol and its derivatives, or a ruthenium derivative), a fluorescent dye (e.g., fluorescein or a fluorescent protein), a radionuclide, or biotin.

[0061] kit In an eighteenth aspect, the present application provides a kit comprising an antibody or antigen-binding fragment thereof of any aspect of the present application, or a conjugate of the present application. In certain embodiments, the kit comprises a conjugate of the present application. In certain embodiments, the kit comprises an antibody or antigen-binding fragment thereof of any aspect of the present application, and optionally a secondary antibody that specifically recognizes the antibody or antigen-binding fragment thereof. Optionally, the secondary antibody also contains a detectable label, such as an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g., an acridinium ester, luminol and its derivatives, or a ruthenium derivative), a fluorescent dye (e.g., fluorescein or a fluorescent protein), a radionuclide, or biotin.

[0062] Detection Method In a nineteenth aspect, the present application provides a method for detecting the presence or level of RSV in a sample, the method comprising using an antibody or antigen-binding fragment thereof of any aspect of the present application, or a conjugate of the present application. In certain embodiments, the methods are used for therapeutic, diagnostic, or non-therapeutic, non-diagnostic purposes.

[0063] In certain embodiments, the method is an immunological assay, such as a Western blotting assay, an enzyme immunoassay (eg, ELISA), a chemiluminescent immunoassay, a fluorescent immunoassay, or a radioimmunoassay. In certain embodiments, the methods include using a conjugate of the present application.

[0064] In certain embodiments, the method includes using an antibody or antigen-binding fragment thereof of any aspect of the present application, and the method further includes using a secondary antibody bearing a detectable label (e.g., an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g., an acridinium ester, luminol and its derivatives, or a ruthenium derivative), a fluorescent dye (e.g., fluorescein or a fluorescent protein), a radionuclide, or biotin) to detect the antibody or antigen-binding fragment thereof.

[0065] In certain embodiments, the method comprises: (1) contacting the sample with an antibody or antigen-binding fragment or conjugate thereof; and (2) detecting the formation of an antigen-antibody immune complex or detecting the amount of the immune complex. In certain embodiments, the formation of an immune complex indicates the presence of RSV or a RSV infected cell.

[0066] Use for manufacturing kits In a twentieth aspect, the present application provides the use of an antibody or antigen-binding fragment thereof of any aspect of the present application, or a conjugate of the present application, in the manufacture of a kit, wherein the kit is used to detect the presence or level of RSV in a sample and / or for diagnostic use, regardless of whether a subject is infected with RSV.

[0067] In certain embodiments, the kit detects the presence or level of RSV in a sample by a method according to the nineteenth aspect. In certain embodiments, the sample is a fluid sample (eg, an airway secretion) or a tissue sample (eg, an airway tissue sample) from a subject (eg, a mammal, preferably a human).

[0068] Definition of Terms In this application, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the virology, biochemistry and immunology testing procedures used herein are routine procedures widely used in the corresponding fields. Meanwhile, in order to better understand the present invention, the definitions and explanations of relevant terms are provided below.

[0069] When the terms "for example," "such as," "eg," "comprising," "including," or variations thereof are used herein, these terms are not to be construed as limiting terms but instead are to be interpreted as meaning "but not limited to" or "including but not limited to."

[0070] Unless otherwise indicated or clearly contradicted by context, the terms "a" and "an," as well as "the," and similar referents in the context of describing this application, and particularly in the context of the claims which follow, are intended to cover both the singular and the plural.

[0071] As used herein, the term "RSV fusion protein" or "F protein" refers to the fusion protein (F protein) of respiratory syncytial virus (RSV), which is well known to those of skill in the art, for example, an exemplary amino acid sequence of which can be found in UniProtKB:P03420.1. In this application, when referring to the amino acid sequence of the F protein, the sequence set forth in SEQ ID NO: 1 is used for illustration. For example, the expression "amino acid residues 160-182 of the F protein" refers to amino acid residues 341-362 of the polypeptide set forth in SEQ ID NO: 1. However, those skilled in the art will understand that mutations or variations (including, but not limited to, substitutions, deletions and / or additions, such as F proteins of different genotypes or subtypes) in the amino acid sequence of gB can be naturally produced or artificially introduced without affecting its biological function. Thus, in this application, the term "F protein" includes all such sequences, including, for example, the sequence set forth in SEQ ID NO: 1 and natural or artificial variants thereof. When describing a sequence fragment of the F protein, it includes not only the sequence fragment of SEQ ID NO: 1, but also the corresponding sequence fragment in its natural or artificial variants. For example, the expression "amino acid residues 160 to 182 of the F protein" includes the amino acid residues of positions 160 to 182 of SEQ ID NO: 1 and the corresponding fragment in its (natural or artificial) variants. According to the present invention, the expression "corresponding sequence fragment" or "corresponding fragment" refers to the fragment at the equivalent position in the sequences to be compared when the sequences are optimally aligned, i.e. when the sequences are aligned for the highest percentage identity.

[0072] As used herein, the term "pre-F protein" refers to an F protein that exists in a pre-F conformation. As used herein, the term "post-F protein" refers to an F protein that exists in a post-F conformation. For a more detailed description of pre-F proteins, post-F proteins, and their conformations, see McLellan et al. (2010), J Vriol, 84: 12236-12244; McLellan et al. (2013), Science, 340: 1113-1117; McLellan et al. (2015), Curr Opin Virol, 11: 70-75; Chinese Patent Application No. 201480013927.7, and PCT International Application No. PCT / CN2014 / 073505, the contents of which are incorporated herein by reference in their entirety for all purposes.

[0073] As used herein, the term "epitope" refers to a portion of an antigen that can be recognized and specifically bound by a particular antibody. When the antigen is a polypeptide, the epitope can be formed by consecutive amino acids or by non-contiguous amino acids assembled by tertiary folding of a protein, and is called a linear epitope or a conformational epitope, respectively. Epitopes formed from consecutive amino acids are typically retained upon protein denaturation, while epitopes formed by tertiary folding are typically lost upon protein denaturation. An epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-contiguous amino acids in a unique spatial conformation.

[0074] As used herein, the term "identity" is used to refer to the sequence match between two polypeptides or two nucleic acids. To measure the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced into the first amino acid sequence or nucleic acid sequence for best alignment with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at the corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., percent identity=number of identical overlapping positions / total number of positions×100%). In certain embodiments, both sequences are of the same length.

[0075] The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, which was improved by Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm was incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403.

[0076] As used herein, the term "antibody" refers to an immunoglobulin molecule that is typically composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC). Antibody light chains can be classified as κ (kappa) and λ (lambda) light chains. Heavy chains can be classified as μ, δ, γ, α or ε, and antibody isotypes are defined as IgM, IgD, IgG, IgA and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with heavy chains also containing a "D" region of about 3 or more amino acids. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region is composed of three domains (CH1, CH2 and CH3). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region is composed of one domain, CL. The constant domains are not directly involved in antibody-antigen binding, but exhibit various effector functions, such as mediating immunoglobulin interactions with host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component of the classical complement system (C1q). The VH and VL regions can also be subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of each heavy / light chain pair (VH and VL), respectively, form an antigen-binding site. The arrangement of amino acids in each region or domain can follow the definitions set forth in Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883.

[0077] As used herein, the term "complementarity determining region" or "CDR" refers to the amino acid residues in an antibody variable region that are involved in antigen binding. The heavy and light chain variable regions each contain three CDRs, designated CDR1, CDR2, and CDR3. The exact boundaries of these CDRs can be defined by various numbering systems well known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883) or the IMGT numbering system (Lefranc et al. al., Dev. Comparat. Immunol. 27:55-77, 2003). For a given antibody, one of skill in the art will readily identify the CDRs defined by each numbering system. Similarly, the correspondence between different numbering systems is well known to those of skill in the art (see, e.g., Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003).

[0078] In the present application, the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention may be determined by various numbering systems well known in the art. In certain embodiments, the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention are preferably determined by the Kabat, Chothia or IMGT numbering system. In certain embodiments, the CDRs contained in the antibody or antigen-binding fragment thereof of the present invention are preferably determined by the IMGT numbering system.

[0079] As used herein, the term "framework region" or "FR" residues refers to amino acid residues in an antibody variable region other than the CDR residues as defined above. The term "antibody" is not limited to any particular method of producing the antibody. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. The antibodies can be of various isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtypes), IgA1, IgA2, IgD, IgE or IgM antibodies.

[0080] As used herein, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen bound by the full-length antibody and / or competes with the full-length antibody for specific binding to an antigen, also referred to as an "antigen-binding component." See generally Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989) (incorporated herein by reference in its entirety for all purposes). Antigen-binding fragments of antibodies can be obtained by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, complementarity determining region (CDR) fragments, scFv, diabodies, single domain antibodies, chimeric antibodies, linear antibodies, nanobodies (technology from Domantis), probodies, and polypeptides comprising at least a portion of an antibody with full antigen-binding ability. Engineered antibody variants are reviewed by Holliger et al., 2005; Nat Biotechnol, 23: 1126-1136.

[0081] As used herein, the term "full-length antibody" refers to an antibody consisting of two "full-length heavy chains" and two "full-length light chains". Among these, "full-length heavy chain" refers to a polypeptide chain consisting of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain and a heavy chain constant region CH3 domain; if the full-length antibody is of the IgE isotype, it optionally further comprises a heavy chain constant region CH4 domain. Preferably, the "full-length heavy chain" is a polypeptide chain consisting of VH, CH1, HR, CH2 and CH3 from the N-terminus to the C-terminus. The "full-length light chain" is a polypeptide chain consisting of a light chain variable region (VL) and a light chain constant region (CL) from the N-terminus to the C-terminus. The two pairs of full-length antibody chains are linked together by disulfide bonds between the CL and CH1 and between the HRs of the two full-length heavy chains. The full-length antibodies of the present invention may be derived from a single species, such as human; they may also be chimeric or humanized antibodies. A full-length antibody of the present invention comprises two antigen-binding sites, each formed by a VH and VL pair, and these two antigen-binding sites specifically recognize / bind the same antigen.

[0082] As used herein, the term "Fd" refers to an antibody fragment consisting of the VH and CH1 domains; the term "dAb fragment" refers to an antibody fragment consisting of the VH domain (Ward et al., Nature 341:544 546 (1989)); the term "Fab fragment" refers to an antibody fragment consisting of the VL, VH, CL and CH1 domains; the term "F(ab')2 fragment" refers to an antibody fragment comprising two Fab fragments linked via a disulfide bridge at the hinge region; the term "Fab' fragment" refers to a fragment obtained after reduction of the disulfide bond linking the two heavy chain fragments in the F(ab')2 fragment and consisting of an intact light chain and an Fd fragment of the heavy chain (consisting of the VH and CH1 domains).

[0083] As used herein, the term "Fv" refers to an antibody fragment consisting of the VL and VH domains of a single arm of an antibody. The Fv fragment is generally considered to be the smallest antibody fragment capable of forming a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a single variable region (e.g., an Fd fragment, which contains only three CDRs specific for an antigen) can recognize and bind an antigen, although with an affinity possibly lower than that of a complete binding site.

[0084] As used herein, the term "Fc" refers to an antibody fragment formed by combining the second and third constant regions of a first heavy chain of an antibody with the second and third constant regions of a second heavy chain via disulfide bonds. The Fc fragment of an antibody has a wide variety of different functions, but is not involved in antigen binding.

[0085] As used herein, the term "scFv" refers to a single polypeptide chain comprising a VL and a VH domain, where the VL and VH are connected via a linker (see, e.g., Bird et al., Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Roseburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. A suitable linker in the prior art may consist of the repeated amino acid sequence GGGGS or a variant thereof. For example, a linker having the amino acid sequence (GGGGS)4 may be used, and variants thereof may also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol may also be used in the present invention. In some cases, there may be a disulfide bond between the VH and VL of the scFv. In certain embodiments of the invention, scFvs can form di-scFvs, where two or more single scFvs are linked in series to form an antibody. In certain embodiments of the present application, scFvs can form (scFv)2, where two or more single scFvs are linked in parallel to form an antibody.

[0086] As used herein, the term "diabody" means a diabody whose VH and VL domains are expressed on a single polypeptide chain, but which uses a linker that is too short to allow pairing between the two domains on the same chain, such that the domains are forced to pair with the complementary domains of another chain and produce two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).

[0087] As used herein, the term "single domain antibody (sdAb)" has the meaning commonly understood by those of skill in the art and refers to an antibody fragment consisting of a single monomeric variable antibody domain (e.g., a single heavy chain variable region), which retains the ability to specifically bind to the same antigen that the full-length antibody binds. Single domain antibodies are also called nanobodies. Each of the above antibody fragments retains the ability to specifically bind to the same antigen that the full-length antibody binds and / or competes with the full-length antibody for specific binding to the antigen.

[0088] Antigen-binding fragments of an antibody (e.g., the antibody fragments described above) can be obtained from a given antibody (e.g., an antibody provided herein) using conventional techniques well known to those of skill in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods), and antigen-binding fragments of an antibody can be screened for specificity in the same manner as intact antibodies. As used herein, unless the context clearly indicates otherwise, when the term "antibody" is referred to it includes not only complete antibodies but also antigen-binding fragments of antibodies.

[0089] As used herein, the term "chimeric antibody" refers to an antibody in which a portion of its light and / or heavy chain is derived from an antibody (which may be from a particular species or may belong to a particular specific antibody class or subclass) and another portion of its light or / and heavy chain is derived from another antibody (which may be from the same or a different species or may belong to the same or a different antibody class or subclass), but in any case retains binding activity to a target antigen (U.S. Pat. No. 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)). In certain embodiments, the term "chimeric antibody" may include antibodies in which the heavy and light chain variable regions of the antibody are derived from a first antibody and the heavy and light chain constant regions of the antibody are derived from a second antibody.

[0090] As used herein, the term "variant" also refers to a polypeptide or peptide that contains an amino acid sequence that has been altered by introducing substitutions, deletions, or additions of amino acid residues in the context of a polypeptide (including a polypeptide). In some cases, the term "variant" also refers to a polypeptide or peptide that has been modified (i.e., by the covalent attachment of any type of molecule to the polypeptide or peptide). For example, and without limitation, a polypeptide may be modified, for example, by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, attachment to cellular ligands or other proteins, and the like. Derivatized polypeptides or peptides may be produced by chemical modification using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like. Furthermore, a variant has similar, identical, or improved function as the polypeptide or peptide from which it is derived.

[0091] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen it targets. The strength and affinity of a specific binding interaction is determined by the equilibrium dissociation constant (K D In this application, the term "K D " refers to the equilibrium dissociation constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the stronger the antibody-antigen binding and the higher the affinity between the antibody and the antigen.

[0092] The specific binding properties between two molecules can be determined using methods well known in the art. One approach involves measuring the rate at which an antigen-binding site / antigen complex forms and dissociates. The "association rate constant" (k a or k on ) and "dissociation rate constant" (k dis or k off ) can be calculated from the concentration and the actual binding and dissociation rates (see Malmqvist M, Nature, 1993, 361:186-187). dis / k on is the dissociation constant K D (See Davies et al., Annual Rev Biochem, 1990; 59:439-473). D , k on , and k dis The value can be measured by any effective method. In certain embodiments, the dissociation constant can be measured by surface plasmon resonance (SPR) using a Biacore instrument. Additionally, bioluminescence interferometry or Kinexa can be used to measure the dissociation constant.

[0093] As used herein, a detectable label according to the present application can be any substance detectable by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical or chemical means. Such labels are well known in the art and include, by way of example and not limitation, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), radionuclides (e.g., 3 H, 125 I, 35 S, 14 C or 32 P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (e.g., Cy7, Alexa 750)), luminescent substances (chemiluminescent substances, e.g., acridinium ester compounds, luminol and its derivative compounds, ruthenium derivatives such as ruthenium terpyridine), magnetic beads (e.g., Dynabeads®), calorimetric markers, such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, and biotin for binding to avidin (e.g., streptavidin) modified with the above labels.

[0094] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. If the vector can be made to express a protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1-derived artificial chromosomes (PACs); phages, such as lambda phages or M13 phages, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papilloma viruses, papova viruses (e.g., SV40). Vectors may contain various elements that regulate expression, including, but are not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, vectors may also contain an origin of replication.

[0095] As used herein, the term "host cell" refers to a cell into which a vector can be introduced, including, but not limited to, a prokaryotic cell, such as Escherichia coli or Bacillus subtilis, a fungal cell, such as a yeast cell or Aspergillus, an insect cell, such as S2 Drosophila cell or Sf9, or an animal cell, such as a fibroblast cell, a CHO cell, a COS cell, an NSO cell, a HeLa cell, a BHK cell, a HEK293 cell or a human cell.

[0096] As used herein, the term "conservative substitution" refers to an amino acid substitution that does not adversely affect or change the expected properties of a protein / polypeptide that contains the amino acid sequence. For example, conservative substitutions can be introduced by standard techniques well known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include the replacement of an amino acid residue with an amino acid residue that has a similar side chain, e.g., the replacement of an amino acid residue with a residue that is physically or functionally similar (e.g., has similar size, shape, charge, chemical properties, including the ability to form covalent or hydrogen bonds). Families of amino acid residues that have similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, it is preferred to replace a corresponding amino acid residue with another amino acid residue from the same side chain family. Methods for identifying conservative amino acid substitutions are well known in the art (see, e.g., Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10):879-884 (1999); and Burks et al. Proc. Natl Acad. Set USA 94:412-417 (1997), which are incorporated herein by reference).

[0097] The description of the 20 conventional amino acids referred to herein follows conventional usage. See, for example, Immunology-A Synthesis (2nd Edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In this application, the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. In this application, amino acids are generally represented by one-letter and three-letter abbreviations well known in the art. For example, alanine can be represented by A or Ala.

[0098] As used herein, the term "pharmaceutical acceptable carriers and / or excipients" refers to carriers and / or excipients that are well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and are pharmacologically and / or physiologically compatible with the subject and the active ingredient, including, but not limited to: pH adjusting agents, surfactants, adjuvants, ionic strength enhancing agents, diluents, agents for maintaining osmotic pressure, agents for delaying absorption, and preservatives. For example, pH adjusting agents include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween®-80. Ionic strength enhancing agents include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents for maintaining osmolarity include, but are not limited to, sugars, NaCl, etc. Agents for delaying absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffer solutions (e.g., buffered saline), alcohols, and polyols (e.g., glycerin), etc. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, etc.Stabilizers have the meaning commonly understood by those skilled in the art and can stabilize the desired activity of the active ingredient in the medicament, including, but not limited to, sodium glutamate, gelatin, SPGA, sugars (e.g., sorbitol, mannitol, starch, sucrose, lactose, dextran or glucose), amino acids (e.g., glutamic acid, glycine), proteins (e.g., dried whey, albumin or casein) or their degradation products (e.g., lactalbumin hydrolysate), etc. In certain exemplary embodiments, the pharma- ceutically acceptable carrier or excipient comprises a sterile injectable liquid (e.g., an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, such sterile injectable fluids are selected from water for injection (WFI), bacteriostatic water for injection (BWFI), a sodium chloride solution (e.g., 0.9% (w / v) NaCl), a dextrose solution (e.g., 5% dextrose), a surfactant-containing solution (e.g., a solution containing 0.01% polysorbate 20), a pH buffer (e.g., phosphate buffered saline), Ringer's solution, and any combination thereof.

[0099] As used herein, the term "prevention" refers to a method carried out to prevent or delay the onset of a disease or condition or symptom in a subject. As used herein, the term "treatment" refers to a method carried out to obtain a beneficial or desired clinical outcome. For the purposes of this application, beneficial or desired clinical outcomes include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, stabilization of the disease state (i.e., not worsening), delaying or slowing disease progression, amelioration or alleviation of the disease state, and alleviation of symptoms (whether partial or total). In addition, "treatment" can also refer to a prolongation of survival compared to the expected survival in the absence of the treatment.

[0100] As used herein, the term "subject" refers to a mammal, such as a human. In certain embodiments, the subject (e.g., a human) has or is at risk for RSV infection or a disease associated with RSV infection (e.g., pneumonia, such as childhood pneumonia).

[0101] As used herein, the term "effective amount" refers to an amount sufficient to achieve or at least partially achieve a desired effect. For example, an effective amount for preventing a disease (e.g., RSV infection or a disease associated with RSV infection (e.g., pneumonia, such as childhood pneumonia)) refers to an amount sufficient to prevent, inhibit or delay the onset of the disease; an effective amount for treating a disease refers to an amount sufficient to cure or at least partially prevent the existing disease and its complications in a patient suffering from the disease. It is well within the capabilities of a person skilled in the art to determine such an effective amount. For example, an effective amount for therapeutic use depends on the severity of the disease to be treated, the general condition of the patient's own immune system, the general condition of the patient, such as age, weight and sex, the mode of drug administration, and other treatments administered at the same time, etc.

[0102] Beneficial Effects of the Invention The monoclonal antibodies and antigen-binding fragments thereof of the present application have a broad spectrum of RSV-binding activity and can specifically bind to the F proteins of multiple RSV strains of type A and / or type B, and can specifically bind to a new epitope located between antigenic site φ and site V on the pre-F protein or a new epitope located between antigenic site II and site V, thereby having high RSV neutralizing activity and effectively preventing RSV infection in vivo.

[0103] The monoclonal antibodies and antigen-binding fragments thereof of the present application can be used to detect, prevent, and / or treat RSV infection or disease caused by RSV infection. In addition, the antibodies of the present application can also be used to specifically detect RSV or its F protein, and thus have clinical value in diagnosing RSV infection.

[0104] Although the embodiments of the present application are described in detail below with reference to the accompanying drawings and examples, those skilled in the art will understand that the following drawings and examples are used to illustrate the present application only and are not intended to limit the scope of the present application. Various objects and advantages of the present application will become apparent to those skilled in the art from the accompanying drawings and the following detailed description of the preferred embodiments. [Brief description of the drawings]

[0105] [Figure 1] FIG. 1 shows experimental results of monoclonal antibodies 5B11, 6B2, and 7G5 neutralizing a representative strain of RSV type A (RSV A2) (panel A) and a representative strain of RSV type B (18537) (panel B). [Diagram 2] FIG. 2 shows the ELISA reactivity of monoclonal antibodies 5B11, 6B2, and 7G5 with pre- and post-fusion proteins of a representative strain of RSV type A and a representative strain of RSV type B; in which panels A and B show the ELISA reactivity results of the respective antibodies with the pre- and post-fusion proteins of a representative strain of RSV type A, respectively; and panels C and D show the ELISA reactivity results of the respective antibodies with the pre- and post-fusion proteins of a representative strain of RSV type B, respectively. [Diagram 3] FIG. 3 shows the broad spectrum binding of monoclonal antibodies 5B11, 6B2 and 7G5 to the F protein of different type A and type B RSV strains. [Figure 4] FIG. 4 shows the three-dimensional structure of monoclonal antibodies 5B11, 6B2 and 7G5 bound to the RSV F protein in the prefusion conformation (DS-Cav1). [Diagram 5] FIG. 5 shows the key amino acid residues involved in the binding of monoclonal antibodies 5B11, 6B2 and 7G5 to the RSV F protein in the prefusion conformation (DS-Cav1). [Figure 6]FIG. 6 shows the results of three-dimensional reconstruction by cryo-electron microscopy of the binding of monoclonal antibody 5B11 to the RSV F protein in the prefusion conformation (DS-Cav1). [Figure 7] 7 shows the protective effect of monoclonal antibodies 5B11, 6B2 and 7G5 in preventing in vivo RSV A2 infection in mice, where Panel A shows the results of weight monitoring of mice from each group; Panel B shows the results of plaque in lung tissue of mice from each group; Panel C shows the results of plaque in nasal tissue of mice from each group; Panel D shows the results of staining pathological sections of lung tissue of mice from each group. [Figure 8] 8 shows nasal and pulmonary virus titers in the evaluation of the preventive effect of monoclonal antibody 5B11 against RSV type A and type B viruses (strains used for type A and type B were RSV A2 and 18537, respectively) in a cotton rat model, where panel A shows the lung virus titer detection results of cotton rats in each group in the evaluation experiment using 5B11 to prevent RSV type A virus; panel B shows the nasal virus titer detection results of cotton rats in each group in the evaluation experiment using 5B11 to prevent RSV type A virus; panel C shows the lung virus titer detection results of cotton rats in each group in the evaluation experiment using 5B11 to prevent RSV type B virus; panel D shows the nasal virus titer detection results of cotton rats in each group in the evaluation experiment using 5B11 to prevent RSV type B virus. [Figure 9] 9 shows the pathology scores of lung tissue in an evaluation of the preventive effect of 5B11 against RSV type A and type B viruses (strains used for type A and type B were RSV A2 and 18537, respectively) in a cotton rat model, where panels A-E show the pathology scores of lung tissue from each group of cotton rats in an evaluation experiment using 5B11 to prevent RSV type A virus; panels F-J show the pathology scores of lung tissue from each group of cotton rats in an evaluation experiment using 5B11 to prevent RSV type B virus. [Figure 10] FIG. 10 shows the design scheme for humanization of 5B11. [Figure 11] FIG. 11 shows the neutralization and reactivity detection of humanized 5B11 antibody; in which panel A shows the detection results of humanized antibody N5B11 in neutralizing RSV type A virus (RSV A2); panel B shows the detection results of humanized antibody N5B11 in neutralizing RSV type B virus (18537); panel C shows the binding detection results of humanized antibody N5B11 to RSV type A (RSV A2) preF; and panel D shows the binding detection results of humanized antibody N5B11 to RSV type B (18537) preF. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0106] Sequence information The following table provides a description of the sequences involved in this application.

[0107] Table 1: Sequence information [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0108] Specific Model for Implementing the Present Application The present application will now be described with reference to the following examples, which are intended to illustrate, but not limit, the present application.

[0109] Unless otherwise specified, the molecular biology experiments and immunoassays used in this application basically refer to the methods described by J. Sambrook et al., Molecular Cloning: Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FM Ausubel et al., Compiled Laboratory Guide to Molecular Biology, 3rd Edition, John Wiley & Sons, Inc., 1995; the use of restriction enzymes is performed according to the conditions recommended by the product manufacturer. If specific conditions are not specified in the examples, they should be performed according to conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or equipment used are not indicated, they were all conventional products that can be purchased commercially. Those skilled in the art will understand that the examples are used to illustrate the present application as examples, without the intention of limiting the scope of the present application. EXAMPLES

[0110] Example 1: Preparation of monoclonal antibodies (McAb) against RSV-F protein (1) Preparation of immunogen: Plasmid DNA-F was kindly donated by the NIH Vaccine Research Center, USA. In this plasmid, the full-length gene of F protein (GenBank: FJ614814.1, SEQ ID NO: 1) of RSV A2 strain was inserted into the VRC8400 vector. In this application, an endotoxin-free plasmid maximum extraction kit (purchased from TianGen, Cat No.: DP117) was used to obtain low endotoxin DNA-F at a concentration of 2mg / mL as an immunogen for mouse immunization. At the same time, in this application, a recombinant adenovirus (rAd-F) containing the full-length gene of F protein (SEQ ID NO: 1) was also prepared for mouse immunization. This recombinant adenovirus was constructed and cryopreserved in our laboratory. As required for mouse immunization, the cryopreserved virus was quickly thawed and used to infect 293β5 cells (239 cells stably transduced with human β5 gene, constructed and stored by our laboratory). Virus was harvested 48 hours post-infection and diluted to 1 × 10 by density gradient centrifugation for subsequent mouse immunization. 10 Concentrated to PFU / mL.

[0111] (2) Laboratory mice: Six-week-old SPF grade female Balb / c mice were purchased from Shanghai Slaccas Laboratory Animal Co., Ltd. (3) Preparation of hybridomas: Standard in vivo immunization and PEG fusion methods were used to obtain monoclonal antibody hybridoma cells, where the detailed methods were referred to Ed Harlow et al., "Antibodies A Laboratory Manual", Cold Spring Harbor Laboratory 1988. A brief process was described as follows:

[0112] (4) Mouse immunization: The immunogen DNA-F (100 μg / mouse) or rAd-F (5 × 10 7PFU / mouse) were injected into mice by high pressure tail vein injection. The immunization cycle of DNA-F was 4 weeks, and the immunization cycle of rAd-F was 2 weeks. To enhance the immune response, mice were subcutaneously injected with complete Freund's adjuvant during primary immunization with DNA-F immunogen; and booster immunization with rAd-F was performed by subcutaneous injection in incomplete Freund's adjuvant. Subsequently, blood was collected weekly from mouse orbit, and then the serum reactivity and serum neutralization titer of mice in each group were detected, and mice with higher serum neutralization antibody titer were selected for spleen immunization. HEp-2 cells infected with RSV A2 for 48 hours were scraped with a cell scraper, centrifuged to remove MEM medium, the cell pellet was resuspended in 500 μL of 1×PBS, and 50 μL of the suspension was taken for spleen immunization. Three days later, the spleens were removed, disrupted, and the splenocytes were isolated and fused with mouse myeloma cells (SP2 / 0) using PEG.

[0113] (5) Cell fusion: First, mouse spleens were removed and disrupted to obtain a suspension of spleen cells, which were then mixed with logarithmic growth phase mouse myeloma cells SP2 / 0. Cell fusion was performed in the presence of PEG1500. The fused cells were resuspended in 400 mL of fusion medium, aliquoted, added to twenty 96-well cell culture plates, and cultured. The fusion medium was RPMI1640 complete selection medium containing HAT and 20% FBS.

[0114] (6) Hybridoma screening: After the fusion cells were cultured in 96-well cell culture plates for 10 days, the cell supernatant was pipetted for virus neutralization experiments and ELISA detection, and the virus used for detection was RSV A2 mKate. During virus neutralization, wells in which antibodies were secreted were defined as positive wells, which could inhibit the infection of Hep2 cells by respiratory syncytial virus; during ELISA detection, wells in which the secreted antibodies could specifically react with respiratory syncytial virus-infected Hep2 cells immobilized on cell plates were defined as positive wells. After cloning the positive clones three times, a monoclonal antibody cell line that could stably secrete antibodies was obtained.

[0115] (7) Hybridoma monoclonal antibody screening results: Nine strains of anti-RSV neutralizing monoclonal antibodies specific for the prefusion protein were obtained, including 5B11, 6B2, and 7G5.

[0116] (8) Hybridoma culture: Nine stable hybridoma monoclonal antibody cell lines were expanded and cultured in a carbon dioxide incubator, then transferred from 96-well to 24-well, and then transferred to 50mL cell culture bottles for expansion and culture. The cells in the cell bottles were then harvested and injected into the peritoneal cavity of mice. After 7-10 days, monoclonal antibody ascites was obtained from the peritoneal cavity of the mice.

[0117] (9) Purification of monoclonal antibodies: The monoclonal antibody ascites was precipitated with 50% ammonium sulfate solution, then the precipitate was dissolved in PBS and purified by protein A column under AKTA system to obtain the purified monoclonal antibody, which was identified by SDS-PAGE to determine the purity of the purified monoclonal antibody.

[0118] Example 2: Neutralizing activity of monoclonal antibodies against RSV F protein Neutralizing activity is an important indicator to evaluate whether a monoclonal antibody has the potential to prevent and treat disease. Microwell cell neutralization experiments were used to detect the neutralizing activity of monoclonal antibodies 5B11, 6B2 and 7G5 obtained in Example 1 against representative strains of respiratory syncytial virus type A and type B, RSV A2, and 18537 (the method is referred to Yong-Peng Sun et al., Journal of Virological Methods. 2018, 260:34-40). The control antibodies used were 5C4 (antibody from mouse screened by our laboratory PCT No. PCT / CN2014 / 073505), D25 (expressed by constructed plasmid, Patent No. US8,568,726B2) and 1129 (the sequence of which was donated by NIH and expressed by constructed plasmid).

[0119] Table 2: Summary of IC50 of each RSV neutralizing antibody [Table 2]

[0120] The results are shown in Table 2 and Figure 1. The results show that monoclonal antibodies 5B11, 6B2 and 7G5 all exhibit better ability to neutralize RSV A2 and 18537 than 1129, where the potency of 5B11 in neutralizing RSV A2 is similar to that of the control antibody 5C4 and is 50-fold greater than the neutralizing potency of 1129, and the potency of 5B11 in neutralizing 18537 is approximately 10-fold greater than that of 1129.

[0121] Example 3: ELISA detection of anti-RSV F protein monoclonal antibody reactivity For the procedure and method of indirect ELISA detection of antigen-antibody binding, please refer to the prior art document (Min Zhao et al., J Biol Chem. 2015, 290(32):19910-22). The detection results are shown in Figure 2, where only three monoclonal antibodies (5B11, 6B2 and 7G5) bind to the F protein of the pre-F conformation (DS-Cav1) of RSV type A and type B viruses, but not to the F protein of the post-F conformation, thereby indicating that they are antibodies that specifically recognize the epitopes that are specifically present on RSV pre-F.

[0122] Example 4: Sequence analysis of light and heavy chain genes of anti-RSV F protein monoclonal antibodies about 10 7Hybridoma cells were subjected to semi-adherent culture: the adherent cells were broken up, suspended, and the suspension was transferred to a new 4 mL centrifuge tube and centrifuged at 1500 rpm for 3 min. The cell pellet was collected and resuspended in 100 μL of sterile PBS (pH=7.45) and transferred to a new 1.5 mL centrifuge tube. 800 μL of Trizol (purchased from Roche, Germany) was added, mixed gently by end-over-end mixing, and allowed to stand for 10 min. 200 μL of chloroform was added, shaken vigorously for 15 s, allowed to stand for 10 min, and centrifuged at 12000 rpm at 4° C. for 15 min. The upper liquid was transferred to a new 1.5 mL centrifuge tube, an equal volume of isopropanol was added, mixed thoroughly, allowed to stand for 10 min, and centrifuged at 12000 rpm at 4° C. for 10 min. The supernatant was discarded, 600 μL of 75% ethanol was added for washing, centrifugation was performed at 4°C, 12000 rpm for 5 minutes, and the supernatant was discarded. The precipitate was vacuum dried at 60°C for 5 minutes. The clear pellet was dissolved in 70 μL of DEPC H2O and divided into two tubes. 1 μL of reverse transcription primer was added to each tube. The reverse transcription primer added to one tube was MVJkR (SEQ ID NO: 27), which was used to amplify the light chain variable region gene. The reverse transcription primer added to the other tube was MVDJhR (SEQ ID NO: 28), which was used to amplify the heavy chain variable region gene. 1 μL of dNTP (purchased from Shanghai Sangon) was added to each tube, and the tube was placed in a 72°C water bath for 10 minutes, and then immediately placed in an ice bath for 5 minutes. 10 μL of 5× reverse transcription buffer, 1 μL of AMV (10 U / μL, purchased from Pormega), and 1 μL of Rnasin (40 U / μL, purchased from Promega) were added, mixed thoroughly, and the RNA was reverse transcribed into cDNA at 42° C.

[0123] The variable regions of the antibody genes were isolated using polymerase chain reaction (PCR) method, in which a primer set synthesized based on Novagen's Ig-Prime kit and two additionally designed and synthesized downstream primers MVJkR and MVDJhR (synthesized by Shanghai Sangon) were used, where MVJkR was the downstream primer for light chain variable region gene amplification, and MVDJhR was the downstream primer for heavy chain variable region gene amplification. The templates were the two cDNAs previously synthesized. The PCR conditions were: 94°C for 5 min, 94°C for 40 sec, 53°C for 1 min, 72°C for 50 sec for 35 cycles, and 72°C for 15 sec. The PCR products were directly sent to Shanghai Sangon for sequencing. The sequences were compared with IMGT to determine the antibody variable region sequences and the corresponding amino acid sequences.

[0124] The antibody variable region genes were obtained by cloning from the 5B11, 6B2 and 7G5 monoclonal antibody hybridoma cell lines according to the above method, and the amino acid sequences of the CDR regions (complementarity determining regions) of the monoclonal antibodies were determined by referring to the IMGT method (Marie-PaμLe Lefranc and Gerard Lefranc. Immunoglobulins or Antibodies: IMGTR Bridging Genes, Structures and Functions, Biomedicines 2020, 8, 319). The variable region and CDR sequences of each antibody (defined by the IMGT numbering system) are shown in Table 1. Table 3 shows the primer sequences used.

[0125] Table 3: Shows the primer sequences used to amplify the variable region genes of the 5B11, 6B2 and 7G5 monoclonal antibodies. [Table 3-1] [Table 3-2] [Table 3-3]

[0126] Example 5: Detection of broad spectrum binding activity of anti-RSV F protein monoclonal antibodies More than 1,000 nucleic acid sequences of RSV F protein were downloaded from NCBI, and evolutionary tree analysis of RSV F protein was performed by MEGA software to select 20 representative RSV F protein sequences, and these 20 sequences were assembled into VRC8400 vector (synthesized by Shanghai Sangon). These plasmids were then transfected into 293 cells, and these proteins were overexpressed on the cell membrane, and the binding of three antibodies 5B11, 6B2 and 7G5 to 293 cells overexpressing F protein was detected by flow cytometry. The experimental results are shown in Figure 3. The results showed that 5B11, 6B2 and 7G5 all had strong broad-spectrum binding activity and could bind well to the F protein of RSV type A and type B strains, that is, they were potential RSV broad-spectrum neutralizing antibodies.

[0127] Example 6: Identification of the three-dimensional structure of the complex between anti-RSV F protein monoclonal antibody and RSV pre-fusion protein (DS-Cav1) and identification of key amino acid residues To clarify the binding epitopes of the three antibodies 5B11, 6B2 and 7G5 to the RSV pre-fusion protein, we prepared antigen-antibody complexes of the antibodies 5B11, 6B2 and 7G5 with the RSV pre-fusion protein (DS-Cav1), respectively, and analyzed the structures of these antigen-antibody complexes by three-dimensional reconstruction techniques using cryo-electron microscopy. The experimental results are shown in Figure 4. The results show that the three antibodies 5B11, 6B2 and 7G5 bound to new epitopes on the RSV pre-fusion protein (DS-Cav1), in which the antibodies 5B11 and 6B2 could specifically bind to a new epitope located between antigenic sites φ and V on the pre-F protein of respiratory syncytial virus, while the antibody 7G5 could specifically bind to a new epitope located between antigenic sites II and V on the pre-F protein of respiratory syncytial virus.

[0128] To further clarify the key amino acid residues involved in the binding of the three antibodies, alanine scanning was performed on the regions of F protein that bind to the three antibodies, i.e., the surface amino acids of F protein were mutated to alanine (A), a mutant plasmid library was constructed by mutation based on DNA-F plasmid, the mutant plasmid was transfected into 293 cells, F protein was overexpressed on the cell surface, and the binding of the three antibodies 5B11, 6B2 and 7G5 to these mutant proteins was detected by flow cytometry. The experimental results are shown in Figure 5, which show that the key amino acid residues involved in the binding of 5B11 are E161, G162, N165, K166 and G184, the key amino acid residues involved in the binding of 6B2 are E161, G162, G184, K293 and E294, and the key amino acid residues involved in the binding of 7G5 are E161, G162 and G184.

[0129] In addition, to further understand the structure-based interaction of antibody 5B11 with RSV F protein, we prepared a 5B11 Fab-DS-Cav1 antigen-antibody complex and obtained a 3.29 Å high-resolution structure of the 5B11 Fab-DS-Cav1 antigen-antibody complex by cryo-electron microscopy (Cryo-EM). The results are shown in Figure 6. The structure shows that 5B11 binds to the F1 subunit on the F protein, and the main binding regions are aa.160-182 and the loop between β6 and β7 (aa.294-295). The heavy chain of 5B11 mainly interacts with the RSV F protein through CDR1 and CDR3; specifically, D31 on CDR1 of the heavy chain of 5B11 forms hydrogen bonds with E295 on the F1 subunit, Y32 forms hydrogen bonds with E294 and E295, S33 forms hydrogen bonds with E161, and H35 on FR2 also interacts with E161 to form hydrogen bonds. Y101 on the heavy chain CDR3 of 5B11 forms hydrogen bonds with K196 on the F1 subunit, and G102 forms hydrogen bonds with N165. The light chain of 5B11 primarily interacts with the RSV F protein through CDR2 and CDR3; specifically, N50 on the heavy chain CDR2 of 5B11 interacts with S169 on the F1 subunit to form a hydrogen bond, and W92 on the heavy chain CDR3 of 5B11 interacts with K166, S180, and S182 on the F1 subunit to form a hydrogen bond.

[0130] Example 7: Evaluation of the protective effect of anti-RSV F protein monoclonal antibodies against RSV virus in the Balb / C model Passive antibody therapy is a potentially effective antiviral treatment approach for the treatment of infectious diseases. In vitro pore neutralization experiments confirmed that the monoclonal antibodies 5B11, 6B2 and 7G5 of the present application have strong neutralizing activity against RSV type A and type B strains, and are characterized by a broad neutralization spectrum and high neutralization titer against respiratory syncytial virus type A and type B strains. Based on the animal model of respiratory syncytial virus A2 strain infection, in the present application, in order to further confirm the anti-respiratory syncytial virus effect of monoclonal antibodies 5B11, 6B2 and 7G5 in vivo, an in vivo demonstration experiment of the monoclonal antibodies in the prevention of RSV A2 strain was carried out on Balb / c mice in a biological safety laboratory, the details of which are as follows:

[0131] (1) Materials and methods Animals: Balb / c mice, SPF grade, 12 weeks old, female, weighing approximately 20 g. Monoclonal antibodies: 5B11, 6B2, 7G5 and 1129 Respiratory syncytial virus strain A2 was purchased from ATCC. Anesthesia: Isoflorane Animal grouping: Mice were sent to the biosafety laboratory for a week in advance to acclimate to the environment. There were 50 mice in total, 10 mice per group and 5 mice per cage. The mice were marked and the weight of each mouse was recorded. The detailed scheme is shown in Table 4.

[0132] Viral infection: Respiratory syncytial virus A2 strain was preinoculated with 5 × 10 7 PFU / mL and the virus inoculation volume was 100 μL / mouse. Prior to inoculation, mice were anesthetized with isoflurane, and then the virus was inoculated intranasally to infect the mice. Monoclonal antibody intervention: Mice in the antibody prevention group were given a low dose of antibody 24 hours before virus infection for prophylaxis. Each mouse was intraperitoneally injected with a dose of 1.5 mg / kg antibody in a volume of 100 μL.

[0133] Observation and Recording: From day 1 to day 12 after virus infection, the changes in body weight and corresponding behavioral characteristics of the mice were recorded daily. On day 5 after infection, 5 mice were selected from each group to detect the virus titers in nasal and lung tissues, as well as the pathological characteristics of the lung tissues.

[0134] Table 4: Experimental scheme for evaluation of the protective effect of anti-RSV F protein antibodies in animals. [Table 4]

[0135] (2) Results and Analysis After infection with RSV A2, a total of 50 mice in five experimental groups, including the positive control group, 5B11, 6B2, 7G5 and 1129 groups, were observed daily for body weight and the presence or absence of hair-flipping events. The body weight monitoring results are shown in panel A of FIG. 7. The body weight of the mice in the positive control group began to decrease on the fourth day after infection, dropped to the nadir on the seventh day, and then gradually recovered. Compared with the 1129 control group, the 5B11, 6B2 and 7G5 groups did not show obvious weight loss, indicating that they could protect mice from weight loss to a certain extent, and their protective effect was superior to that of the 1129 control group. During the experiment, it was found that the mice in the positive control group and the 1129 control group had obvious hair-flipping events on the fifth day after infection, whereas no obvious hair-flipping events were observed in the other groups.

[0136] The results of viral plaques in the nose and lung tissues are shown in panels C and B of Figure 7, respectively. From the plaque detection results in the lung tissues, the viral titers in the lung tissues of mice in the positive group and the 1129 control group were relatively high, at 10 5.4 PFU / g and 10 4.9PFU / g was reached; meanwhile, no virus was detected in the 5B11, 6B2 and 7G5 groups, and there was a statistically significant difference with the positive group and the 1129 control group (P<0.05). In addition, the three antibody strains (5B11, 6B2 and 7G5) could also reduce the viral infection of the upper respiratory tract and nose to a certain extent, and their effects were superior to those of the 1129 control group (Panel C of FIG. 7). In summary, the three antibody strains (5B11, 6B2 and 7G5) could prevent upper and lower respiratory tract infection at low doses.

[0137] According to the pathological characteristics of the lung tissue (panel D of FIG. 7), in the positive group and the 1129 control group, many infiltrating inflammatory cells appeared in the blood vessels, bronchiole, bronchioles, and alveolar walls of the mouse lung tissue, the swelling was prominent, and in some severe cases, the cell space was compressed and the alveolar walls were destroyed. It could be seen from the pathological sections of the 6B2 and 7G5 antibody groups that the lung tissue contained minor pathological signs, the blood vessel walls, bronchiole walls, and bronchioles walls were thickened, and minor inflammatory cell infiltration could be seen around them, but the alveolar structure was intact and complete, and there was no obvious inflammatory cell infiltration and thickening. In the mice of the 5B11 group, there was no inflammatory cell infiltration in the blood vessels, bronchiole, bronchioles, and alveolar walls of the lung tissue, and their morphology and structure were normal.

[0138] The above experimental results showed that the low-dose prophylaxis experiments showed that the prophylactic effects of the three antibodies 5B11, 6B2 and 7G5 at the same dose were superior to those of the 1129 control group, and suggested that they could effectively prevent RSV infection, reduce weight loss and symptoms in mice, inhibit viral replication in the upper and lower respiratory tract, and reduce inflammatory responses, etc.

[0139] Example 8: Evaluation of the protective efficacy of 5B11 monoclonal antibody against RSV virus in a cotton rat model (1) Evaluation of the prophylactic effect of 5B11 against RSV type A virus in a cotton rat model To investigate whether 5B11 has the potential to be a prophylactic drug for RSV, the present application further evaluated the preventive effect of 5B11 against RSV type A virus in a cotton rat model. The groupings designed for the experiment are shown in Table 5, and there were a total of 5 groups, with 5 cotton rats in each group. For the antibody group, the antibody was pre-diluted with PBS to 15 mg / mL and 1.5 mg / mL for subsequent use with high dose (15 mg / kg) and low dose (1.5 mg / kg); the day before challenge (day -1), each rat was intramuscularly injected with the antibody in the right hind leg at a specific volume according to the rat's weight; 24 hours later (day 0), 2×10 7 100 μL of RSV A2 virus with a titer of PFU / mL was administered intranasally. For the PBS group, 100 μL of PBS was injected intramuscularly into the right hind leg of each cotton rat on the day before challenge; 24 hours later, 2×10 7 100 μL of RSV A2 virus with titers in PFU / mL was administered intranasally. Five days after challenge, cotton rats from each group were euthanized using CO2, and nasal and lung tissues were collected by necropsy for evaluation of viral titers in nasal and lung tissues, and nasal and lung pathology inflammation.

[0140] Table 5: Grouping for the study evaluating the protective effect of RSV F protein antibodies in cotton rats [Table 5]

[0141] Lung plaque detection results (Panel A of FIG. 8) showed that no viral titers were detected in the lungs of the high and low dose groups of 5B11, suggesting that 5B11 may completely prevent RSV lung infection at low doses; for 1129, only the high dose group showed no viral titers detected, completely preventing RSV lung infection; on the other hand, higher viral titers were detected in the low dose group of 1129, indicating that the viral infection was reduced by 25-fold (1.4 Log) when compared with the PBS group, and it may only prevent viral lung infection to some extent.

[0142] The nasal viral plaque detection results (Panel B of FIG. 8) showed that the high and low dose groups of 5B11 and the high dose group of 1129 all had statistically significant differences when compared with the PBS group, indicating that nasal RSV infection could be completely prevented in the high dose group of 5B11, and the viral infection was reduced 500-fold (2.7 logs) compared with the PBS group, the viral infection was reduced 5-fold (0.7 logs) in the low dose group of 1129 compared with the PBS group, and the viral infection was reduced 50-fold (1.7 logs) in the high dose group of 1129 compared with the PBS group, indicating that none of them could completely prevent nasal viral infection in rats.

[0143] The pathological inflammation in the lung tissue of each group was quantified and scored according to the degree of inflammatory cell infiltration at different sites, and the difference in the inflammation scores between the groups was calculated by analysis of variance. The lung pathological scores (panels A-E in FIG. 9) showed that perivascular inflammation and interstitial pneumonia were not obvious in the cotton rats of each group, while the lung inflammation of the PBS group mainly exhibited severe tracheitis, bronchitis, and alveolitis. No obvious vasculitis, tracheitis, bronchitis, alveolitis, and interstitial pneumonia was seen in the high-dose and low-dose groups of 5B11. The high-dose and low-dose groups of 1129 showed tracheitis and bronchitis, in which the tracheitis and bronchitis were mild in the high-dose group of 1129, while the tracheitis and bronchitis were more severe in the low-dose group of 1129. The above results suggest that 5B11 has high potential to inhibit pulmonary inflammation, and low doses of 5B11 may achieve or even surpass the ability of high doses of 1129 to inhibit pulmonary inflammation.

[0144] (2) Evaluation of the prophylactic effect of 5B11 against RSV type B virus in a cotton rat model In this application, the evaluation of the preventive effect of 5B11 against RSV type B virus was further carried out in a cotton rat model. The groupings designed in the experiment are shown in Table 6, and there were a total of 5 groups, with 4-5 cotton rats in each group. For the antibody group, the antibody was pre-diluted with PBS to 15 mg / mL and 1.5 mg / mL for subsequent use with high dose (15 mg / kg) and low dose (1.5 mg / kg). The day before antigen challenge (day -1), each rat was intramuscularly injected with the antibody in the right hind leg at a specific volume according to the rat's body weight; 24 hours later (day 0), 3.8 × 10 6 100 μL of RSV B 18537 virus with a titer of PFU / mL was administered intranasally. For the PBS group, 100 μL of PBS was injected intramuscularly into the right hind leg of each cotton rat the day before challenge; 24 hours later, 3.8×10 6 100 μL of RSV B 18537 virus with a titer of PFU / mL was administered intranasally, and the detection index was the same as in the prevention experiment of 5B11 against RSV type A virus in the cotton rat model.

[0145] Table 6: Grouping for the experiment evaluating the protective effect of RSV F protein antibodies on cotton rats [Table 6]

[0146] Lung viral plaque detection results (panel C of FIG. 8) showed that higher viral titers could be detected in the PBS group, and the high and low dose groups of 5B11 and the high and low dose groups of 1129 all had statistically significant differences compared with the PBS group. No viral titers were detected in the lungs of the high and low dose groups of 5B11, suggesting that 5B11 can completely prevent RSV lung infection at low doses; only the high dose group of 1129 had no viral titers detected and completely prevented RSV lung infection, while higher viral titers were detected in the low dose group of 1129, indicating that the viral infection was reduced by 10-fold (1 Log) when compared with the PBS group, and it may only inhibit viral lung infection to a certain extent.

[0147] Nasal viral plaque detection results (FIG. 8, panel D) showed that higher viral titers were detected in the PBS group, and the 5B11 high and low dose groups, as well as the 1129 high dose group, all had statistically significant differences when compared to the PBS group, where nasal RSV infection was completely prevented in the 5B11 high dose group, and viral infection was reduced 63-fold (1.8 logs) in the 5B11 low dose group compared to the PBS group, viral infection was reduced 4-fold (0.6 logs) in the 1129 low dose group compared to the PBS group, and viral infection was reduced 1995-fold (3.3 logs) in the 1129 high dose group compared to the PBS group.

[0148] The pathological inflammation in the lung tissue of each group was quantified and scored according to the degree of inflammatory cell infiltration at different sites, and the difference in the inflammation scores between the groups was calculated by analysis of variance. The lung pathological scores (panels F-J in FIG. 9) showed that perivascular inflammation, alveolitis, and interstitial pneumonia were not evident in the cotton rats of each group, while the lung inflammation of the PBS group mainly exhibited severe tracheitis and bronchitis. As for the high-dose group of 5B11, there was no obvious perivascular inflammation, tracheitis, bronchitis, alveolitis, and interstitial pneumonia. Compared with the PBS group and the low-dose group of 1129, the tracheitis was alleviated to some extent in the low-dose group of 5B11, but there was no statistically significant difference. The high-dose group of 1129 was similar to the high-dose group of 5B11 and did not show obvious tracheitis or bronchitis. However, one cotton rat each from the high-dose and low-dose groups of 1129 developed severe alveolitis and interstitial pneumonia, which may be due to individual differences in the experimental animals.

[0149] In summary, 5B11 at high and low doses can completely inhibit RSV A / B virus infection in the lower respiratory tract, and at low doses 5B11 can also effectively reduce RSV A / B virus infection in the upper respiratory tract, where the virus was reduced by 500-fold and 63-fold, respectively. In addition, no obvious lung inflammation was observed in the high and low dose groups of 5B11, suggesting that 5B11 at low doses can effectively protect cotton rats from inflammation caused by viral infection, and that 5B11 can achieve the desired protective effect at 1 / 10 of the dose of 1129.

[0150] Example 9: Humanized 5B11 monoclonal antibody and evaluation of its neutralizing activity and reactivity Since 5B11 is a mouse-derived antibody and has good immunogenicity, 5B11 needed to be humanized to reduce the immunogenicity of 5B11. The principles of humanization design were as follows: 1) the light and heavy chains of 5B11 antibody were aligned with human germline gene sequences with the highest homology, respectively; 2) the amino acids in FRs at the CDR interface or located near CDRs were usually retained (amino acids marked in red), since these amino acids may play an important role in the binding between antigen and antibody, whereas the amino acids far from CDRs and not hydrophobic were usually mutated immediately; 3) the amino acids in FRs at the VH-VK interface were usually retained (amino acids marked in blue); 4) the antibody structure was simulated to obtain exposed amino acids and buried amino acids, and the buried amino acids were selectively retained (because they may affect the binding between antigen and antibody) (amino acids marked in green); 5) the exposed amino acids and the remaining amino acids, which have little effect on the antibody activity, were mutated immediately (amino acids marked in black). After humanization, the humanized 5B11 was designated as N5B11, and its degree of humanization was 90% (FIG. 10). The amino acid sequences of the light chain variable region and the heavy chain variable region of the humanized antibody N5B11 are set forth in SEQ ID NOs: 60 and 61, respectively.

[0151] The genes of the heavy and light chain variable regions of N5B11 were assembled into the PTT5 eukaryotic expression vector encoding the human immunoglobulin constant region stored in the laboratory, and the plasmids PTT5-N5B11-heavy chain (containing the nucleotide sequence encoding the heavy chain constant region as set forth in SEQ ID NO: 62) and PTT5-N5B11-light chain (containing the nucleotide sequence encoding the light chain constant region as set forth in SEQ ID NO: 63) were constructed, respectively, and the double plasmids were transiently transferred into expi-293 cells for expression, and the supernatant was collected after 7 days, and protein A was used to purify the supernatant to obtain the antibody N5B11. Then, the neutralizing activity and binding activity of the purified N5B11 were detected (methods for detecting the neutralizing activity and binding activity were referred to Example 2 and Example 3, respectively). The experimental results showed that the neutralizing activity (panels A-B in FIG. 11) and binding activity (panels C-D in FIG. 11) of the humanized antibody N5B11 were consistent with those of the mouse antibody 5B11.

[0152] Although specific embodiments of the present application have been described in detail, those skilled in the art will fully understand, based on all the teachings disclosed herein, various modifications and variations therein, and will understand that these variations fall within the scope of the present application, the full scope of which is given by the appended claims and any equivalents thereof.

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to an epitope of a respiratory syncytial virus (RSV) pre-F protein, wherein the epitope includes at least six amino acid residues (e.g., non-contiguous amino acid residues) within amino acid residues 294-295 and amino acid residues 160-182 of the pre-F protein; Preferably, the epitope comprises at least amino acid residues at positions 161, 165, 166, 169, 180, 182, 294, and 295; Preferably, the epitope further comprises the amino acid residue at position 196; Preferably, the epitope further comprises amino acid residues at positions 162 and 184; Preferably, the epitope comprises amino acid residues 161-182 (e.g., amino acid residues 161-184) and amino acid residues 294-295; Preferably, the epitope is a conformational epitope; Preferably, the amino acid residue positions are determined according to SEQ ID NO:1; Preferably, the epitope comprises at least E161, N165, K166, S169, S180, S182, E294, and E295; preferably, the epitope further comprises K196; preferably, the epitope further comprises G162 and G184. The antibody or antigen-binding fragment thereof.

2. below: (a) a heavy chain variable region (VH) comprising the following three CDRs: a VH CDR1 comprising the sequence set forth in SEQ ID NO: 5 or a variant thereof, a VH CDR2 comprising the sequence set forth in SEQ ID NO: 6 or a variant thereof, and a VH CDR3 comprising the sequence set forth in SEQ ID NO: 7 or a variant thereof; and / or (b) a light chain variable region (VL) comprising the following three CDRs: a VL CDR1 comprising the sequence set forth in SEQ ID NO: 8 or a variant thereof, a VL CDR2 comprising the sequence set forth in SEQ ID NO: 9 or a variant thereof, and a VL CDR3 comprising the sequence set forth in SEQ ID NO: 10 or a variant thereof; Including, wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or wherein the variant has one or more amino acid substitutions, deletions, or additions (e.g., one, two, or three amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived; preferably, the substitutions are conservative substitutions; Preferably, it is capable of specifically binding to the RSV pre-F protein; Preferably, it competes with the antibody or antigen-binding fragment thereof of claim 1 for binding to the RSV pre-F protein; Preferably, it binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of claim 1. The antibody or antigen-binding fragment thereof.

3. (i) comprises three heavy chain CDRs: a VH CDR1 having the sequence set forth in SEQ ID NO:5, a VH CDR2 having the sequence set forth in SEQ ID NO:6, and a VH CDR3 having the sequence set forth in SEQ ID NO:7; and / or three light chain CDRs: a VL CDR1 having the sequence set forth in SEQ ID NO:8, a VL CDR2 having the sequence set forth in SEQ ID NO:9, and a VL CDR3 having the sequence set forth in SEQ ID NO:10; and / or (ii) comprising three CDRs contained in a heavy chain variable region (VH) as set forth in SEQ ID NO: 3 or 60; and / or three CDRs contained in a light chain variable region (VL) as set forth in SEQ ID NO: 4 or 61; preferably, the three CDRs contained in the VH and / or the three CDRs contained in the VL are as defined by the Kabat, IMGT or Chothia numbering system.

3. The antibody or antigen-binding fragment thereof according to claim 1 or 2.

4. below: a VH comprising a sequence as set forth in SEQ ID NO:3 or a variant thereof, and / or a VL comprising a sequence as set forth in SEQ ID NO:4 or a variant thereof; wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or the variant has one or more amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived; preferably, the substitutions are conservative substitutions; Preferably, the VH is as set forth in SEQ ID NO: 3 and / or the VL is as set forth in SEQ ID NO:

4. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.

5. An antibody or antigen-binding fragment thereof that specifically binds to an epitope of a respiratory syncytial virus (RSV) pre-F protein, wherein the epitope includes at least five amino acid residues (e.g., non-contiguous amino acid residues) within amino acid residues 160-185 and 290-295 of the pre-F protein; Preferably, the epitope comprises at least amino acid residues at positions 161, 162, 184, 293 and 294; Preferably, the epitope comprises amino acid residues 161-182 and 293-294; Preferably, the epitope is a conformational epitope; Preferably, the amino acid residue positions are determined according to SEQ ID NO:1; Preferably, the epitope comprises at least E161, G162, G184, K293 and E294. The antibody or antigen-binding fragment thereof.

6. below: (a) a heavy chain variable region (VH) comprising the following three CDRs: a VH CDR1 comprising the sequence set forth in SEQ ID NO: 13 or a variant thereof, a VH CDR2 comprising the sequence set forth in SEQ ID NO: 14 or a variant thereof, and a VH CDR3 comprising the sequence set forth in SEQ ID NO: 15 or a variant thereof; and / or (b) a light chain variable region (VL) comprising the following three CDRs: a VL CDR1 comprising the sequence set forth in SEQ ID NO: 16 or a variant thereof, a VL CDR2 comprising the sequence set forth in SEQ ID NO: 17 or a variant thereof, and a VL CDR3 comprising the sequence set forth in SEQ ID NO: 18 or a variant thereof; Including, wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or wherein the variant has one or more amino acid substitutions, deletions, or additions (e.g., one, two, or three amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived; preferably, the substitutions are conservative substitutions; Preferably, it is capable of specifically binding to the RSV pre-F protein; Preferably, competes with the antibody or antigen-binding fragment thereof of claim 5 for binding to the RSV pre-F protein; Preferably, it binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of claim 5. The antibody or antigen-binding fragment thereof.

7. (i) comprises three heavy chain CDRs: a VH CDR1 having the sequence set forth in SEQ ID NO: 13, a VH CDR2 having the sequence set forth in SEQ ID NO: 14, and a VH CDR3 having the sequence set forth in SEQ ID NO: 15; and / or three light chain CDRs: a VL CDR1 having the sequence set forth in SEQ ID NO: 16, a VL CDR2 having the sequence set forth in SEQ ID NO: 17, and a VL CDR3 having the sequence set forth in SEQ ID NO: 18; and / or (ii) comprising three CDRs contained in a heavy chain variable region (VH) as set forth in SEQ ID NO: 11; and / or three CDRs contained in a light chain variable region (VL) as set forth in SEQ ID NO: 12; preferably, the three CDRs contained in the VH and / or the three CDRs contained in the VL are as defined by the Kabat, IMGT or Chothia numbering systems.

7. The antibody or antigen-binding fragment thereof according to claim 5 or 6.

8. below: a VH comprising a sequence as set forth in SEQ ID NO: 11 or a variant thereof, and / or a VL comprising a sequence as set forth in SEQ ID NO: 12 or a variant thereof; wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or the variant has one or more amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived; preferably, the substitutions are conservative substitutions; Preferably, the VH is as set forth in SEQ ID NO: 11, and / or the VL is as set forth in SEQ ID NO:

12. An antibody or antigen-binding fragment thereof according to any one of claims 5 to 7.

9. An antibody or antigen-binding fragment thereof that specifically binds to an epitope of a respiratory syncytial virus (RSV) pre-F protein, wherein the epitope includes at least three amino acid residues (e.g., non-contiguous amino acid residues) within amino acid residues 160 to 185 of the pre-F protein; Preferably, the epitope comprises at least amino acid residues at positions 161, 162, and 184; Preferably, the epitope comprises amino acid residues 161 to 182; Preferably, the epitope is a conformational epitope; Preferably, the amino acid residue positions are determined according to SEQ ID NO:1; Preferably, the epitope comprises at least E161, G162, and G184. The antibody or antigen-binding fragment thereof.

10. below: (a) a heavy chain variable region (VH) comprising the following three CDRs: a VH CDR1 comprising the sequence set forth in SEQ ID NO: 21 or a variant thereof, a VH CDR2 comprising the sequence set forth in SEQ ID NO: 22 or a variant thereof, and a VH CDR3 comprising the sequence set forth in SEQ ID NO: 23 or a variant thereof; and / or (b) a light chain variable region (VL) comprising the following three CDRs: a VL CDR1 comprising the sequence set forth in SEQ ID NO: 24 or a variant thereof, a VL CDR2 comprising the sequence set forth in SEQ ID NO: 25 or a variant thereof, and a VL CDR3 comprising the sequence set forth in SEQ ID NO: 26 or a variant thereof; Including, wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or wherein the variant has one or more amino acid substitutions, deletions, or additions (e.g., one, two, or three amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived; preferably, the substitutions are conservative substitutions; Preferably, it is capable of specifically binding to the RSV pre-F protein. Preferably, competes with the antibody or antigen-binding fragment thereof of claim 9 for binding to the RSV pre-F protein; Preferably, it binds to the same epitope of the RSV pre-F protein as the antibody or antigen-binding fragment thereof of claim 9. The antibody or antigen-binding fragment thereof.

11. (i) the antibody or antigen-binding fragment thereof comprises: three heavy chain CDRs: a VH CDR1 having the sequence set forth in SEQ ID NO: 21, a VH CDR2 having the sequence set forth in SEQ ID NO: 22, and a VH CDR3 having the sequence set forth in SEQ ID NO: 23; and / or three light chain CDRs: a VL CDR1 having the sequence set forth in SEQ ID NO: 24, a VL CDR2 having the sequence set forth in SEQ ID NO: 25, and a VL CDR3 having the sequence set forth in SEQ ID NO: 26; and / or (ii) the antibody or antigen-binding fragment thereof comprises: three CDRs contained in a heavy chain variable region (VH) defined in SEQ ID NO: 19; and / or three CDRs contained in a light chain variable region (VL) defined in SEQ ID NO: 20; preferably, the three CDRs contained in the VH and / or the three CDRs contained in the VL are as defined by the Kabat, IMGT or Chothia numbering systems.

11. The antibody or antigen-binding fragment thereof according to claim 9 or 10.

12. below: a VH comprising a sequence as set forth in SEQ ID NO: 19 or a variant thereof, and / or a VL comprising a sequence as set forth in SEQ ID NO: 20 or a variant thereof; wherein the variant has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to the sequence from which it is derived, or the variant has one or several amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions) compared to the sequence from which it is derived; preferably, the substitutions are conservative substitutions; Preferably, the VH is as set forth in SEQ ID NO: 19, and / or the VL is as set forth in SEQ ID NO:

20. An antibody or antigen-binding fragment thereof according to any one of claims 9 to 11.

13. Humanized; Preferably, it comprises framework region sequences derived from a human immunoglobulin; Preferably, the heavy chain framework region sequence is derived from a human heavy chain germline sequence and the light chain framework region sequence is derived from a human light chain germline sequence; Preferably, the VH is as set forth in SEQ ID NO: 60 and / or the VL is as set forth in SEQ ID NO:

61. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 12.

14. Further comprising a constant region derived from a mouse or human immunoglobulin; Preferably, the heavy chain comprises a heavy chain constant region derived from a mouse or human immunoglobulin (e.g., IgG1, IgG2, IgG3, or IgG4) and the light chain comprises a light chain constant region derived from a mouse or human immunoglobulin (e.g., an immunoglobulin containing a κ or λ chain); Preferably, the heavy chain comprises a heavy chain constant region as set forth in SEQ ID NO: 62, and the light chain comprises a light chain constant region as set forth in SEQ ID NO:

63. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 13.

15. The antigen-binding fragment may be Fab, Fab', (Fab') 2 15. The antibody or antigen-binding fragment thereof of any one of claims 1 to 14, wherein the antibody is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, a bispecific antibody or a multispecific antibody.

16. Features: (a) neutralizes RSV (e.g., RSV type A and / or type B) in vitro or in a subject (e.g., a human); (b) disrupting or inhibiting RSV (e.g., RSV type A and / or type B) from fusing with a cell in vitro or in a subject (e.g., a human); (c) preventing and / or treating RSV (e.g., RSV type A and / or type B) infection or disease associated with RSV (e.g., RSV type A and / or type B) infection (e.g., pneumonia, such as childhood pneumonia); The antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, comprising one or more of the following:

17. An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, or the heavy chain variable region and / or light chain variable region thereof, according to any one of claims 1 to 16.

18. 18. A vector comprising the nucleic acid molecule of claim 17; preferably the vector is a cloning vector or an expression vector.

19. 19. A host cell comprising the nucleic acid molecule of claim 17 or the vector of claim 18.

20. 20. A method for preparing an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, comprising culturing a host cell according to claim 19 under conditions allowing expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the culture of the cultured host cell.

21. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, and a pharma- ceutical acceptable carrier and / or excipient.

22. 20. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16 in the manufacture of a medicament, wherein the medicament is used to neutralize the virulence of RSV, or to inhibit or prevent the fusion of RSV with a cell, or to prevent and / or treat respiratory syncytial virus infection or a disease associated with respiratory syncytial virus infection (e.g. pneumonia, such as childhood pneumonia) in a subject; Preferably, the subject is a mammal, such as a human; Preferably, said use, wherein the antibody or antigen-binding fragment thereof is used alone or in combination with an additional medicamentously active agent.

23. 23. A method for preventing and / or treating respiratory syncytial virus infection or a disease associated with respiratory syncytial virus infection (e.g., pneumonia such as childhood pneumonia) in a subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof described in any one of claims 1 to 16, or a pharmaceutical composition described in claim 21.

24. A conjugate comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16 and a detectable label attached to said antibody or antigen-binding fragment thereof; Preferably, the conjugate wherein the detectable label is selected from the group consisting of an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g., acridinium ester, luminol and its derivatives, or ruthenium derivatives), a fluorescent dye (e.g., fluorescein or a fluorescent protein), a radionuclide or biotin.

25. A kit comprising an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 16, or a conjugate according to claim 24, Preferably comprising a conjugate according to claim 24; Preferably, said kit comprises an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, and optionally a secondary antibody which specifically recognises said antibody or antigen-binding fragment thereof; optionally, said secondary antibody also comprises a detectable label, such as an enzyme (e.g. horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g. acridinium ester, luminol and its derivatives, or ruthenium derivatives), a fluorescent dye (e.g. fluorescein or a fluorescent protein), a radionuclide or biotin.

26. A method for detecting the presence or level of RSV in a sample, comprising using an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, or a conjugate according to claim 24, Preferably, the method is an immunological assay, such as an immunoblotting assay, an enzyme immunoassay (e.g., ELISA), a chemiluminescent immunoassay, a fluorescent immunoassay, or a radioimmunoassay; Preferably, the method comprises using a conjugate according to claim 24; Preferably, the method comprises using an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, and further comprises using a secondary antibody carrying a detectable label (e.g. an enzyme (e.g. horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g. acridinium ester, luminol and its derivatives, or ruthenium derivatives), a fluorescent dye (e.g. fluorescein or a fluorescent protein), a radionuclide or biotin) for detecting the antibody or antigen-binding fragment thereof; Preferably, the method comprises: (1) contacting a sample with an antibody or an antigen-binding fragment or conjugate thereof; and (2) detecting the formation of an antigen-antibody immune complex or detecting the amount of an immune complex; preferably, the formation of the immune complex indicates the presence of RSV or an RSV-infected cell.

27. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, or a conjugate according to claim 24, in the manufacture of a kit, wherein the kit is used for detecting the presence or level of RSV in a sample and / or for diagnosis, whether or not a subject is infected with RSV; Preferably, the kit detects the presence or level of RSV in a sample by the method of claim 26; Preferably, said use, wherein the sample is a body fluid sample (eg, an airway secretion) or a tissue sample (eg, an airway tissue sample) from a subject (eg, a mammal, preferably a human).

Citation Information

Patent Citations

  • Epitope of RSV fusion protein and antibody that recognizes the epitope

    JP2016516400A

  • Antibodies that neutralize RSV, MPV and PVM and uses thereof

    US20170121393A1

  • Anti-respiratory syncytial virus antibodies, and methods of their generation and use

    US20190256581A1